DCTPep_ID,Cell_Line,Disease,Cancer_Classified,Activity,Sequence,Sequence_Length,Origin,Type,Nature,Classification,Molecular_weight_average,Molecular_weight_monoisotopic,pI,Absent_amino_acids,Common_amino_acids,Formula,Net_charge,Ext,Half_Life,Instability_index,Aliphatic_index,GRAVY,Literature_y,Label,Peptide_Name,N-terminal_Modification,C-terminal_Modification
DCTPep01604,PC-3,Prostate carcinoma,Carcinoma,LD50=11 µg/ml,FAKFLAKFLKKAL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1524.96,1523.96,10.48,CDEGHIMNPQRSTVWY,K,C78H125N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",2.7,113.08,0.738,Not available++Not available++Not available++Not available,1,,,
DCTPep00278, --, --, --,IC50 for MDM2=0.01 µM,PRFWEYWLRLME,12,E3 ubiquitin-protein ligase,Synthetic peptide,Anticancer; Antitumor,ACP##Tumor active peptide##Cancer targeted peptides##Affect cell cycle,1726.03,1724.85,6.57,ACDGHIKNQSTV,ELRW,C84H116N20O18S1,0,Ext. coefficient    12490##Abs 0.1% (=1 g/l)   7.236,">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",20.57,65.00,-0.700,21423613++mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction++10.1371/journal.pone.0017898++2011,1,,,
DCTPep00010,Brain tumor cell (NCI),Brain tumor,Carcinoma,LC50=10 µM,GLFDIVKKIAGHIVSSI,17,Southern bell frog,Native peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,1797.17,1796.06,8.60,CEMNPQRTWY,I,C84H141N21O22,2,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",37.17,154.71,1.053,10951191++The antibiotic and anticancer active aurein peptides from the Australian Bell Frogs Litoria aurea and Litoria raniformis the solution structure of aurein 1.2++10.1046/j.1432-1327.2000.01536.x++2000,1,,,
DCTPep00279,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,IC50=7.6 μM,GLPVCGETCAGGTCNTPGCSCSWPICTRN,29,Viola abyssinica of the Ethiopian Highlands,Native peptide,Anticancer,ACP##Tumor active peptide,2888.29,2886.17,5.96,DFHKMQY,C,C115H183N35O40S6,0,"Ext. coefficient     5875##Abs 0.1% (=1 g/l)   2.034, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.904, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",45.48,40.34,0.076,21434649++Cyclotides from an extreme habitat: characterization of cyclic peptides from Viola abyssinica of the Ethiopian highlands++10.1021/np100790f++2011,1,,,
DCTPep00505,HCT 116,Colon carcinoma,Carcinoma,Cell viability >50% at 12.5μM approx,KILRGVAKKIMRTFLRRILTGKK,23,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane lysis,2727.49,2725.75,12.49,CDEHNPQSWY,K,C124H228N40O26S1,9,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",51.6,118.70,-0.178,24962950++Host defense peptides for treatment of colorectal carcinoma - a comparative in vitro and in vivo analysis++10.18632/oncotarget.2039++2014,1,,,
DCTPep00265,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,27% Cytotoxicity at 0.5 µg/ml,ILRWPWWPWRRK,12,Helical peptide with a predominance of one or more amino acids tryptophane-rich,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide,1780.16,1779,12.30,ACDEFGHMNQSTVY,W,C90H126N26O13,4,Ext. coefficient    22000##Abs 0.1% (=1 g/l)  12.358,"20 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",131.93,65.00,-1.325,21403917++Antitumor activity of antimicrobial peptides against U937 histiocytic cell line++Not available++2011##8573171++A novel antimicrobial peptide from Bufo bufo gargarizans++10.1006/bbrc.1996.0071++1996,1,,,
DCTPep01703,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=240 µg/ml,FAVGLRAIKRALKKLRRGVRKVAKDL,26,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2963.7,2961.9,12.19,CEHMNPQSTWY,KR,C134H244N46O29,9,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",39.41,123.85,-0.154,Not available++Not available++Not available++Not available,1,,,
DCTPep00262,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,5% Cytotoxicity at 0.5 µg/ml,TRSSRAGLQFPVGRVHRLLRK,21,Bufo Bufo Gargarizans,Native peptide,Anticancer; Antimicrobial,Antiangiogenic,2434.88,2433.43,12.60,CDEIMNWY,R,C106H184N40O26,7,Should not be visible by UV spectrophotometry.,"7.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",84.2,88.10,-0.638,21403917++Antitumor activity of antimicrobial peptides against U937 histiocytic cell line++Not available++2011##8573171++A novel antimicrobial peptide from Bufo bufo gargarizans++10.1006/bbrc.1996.0071++1996,1,,,
DCTPep01624,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=170 µg/ml,FAKKLAKKLKKLAKLALAL,19,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2096.76,2095.43,10.78,CDEGHIMNPQRSTVWY,K,C102H186N26O20,7,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.87,149.47,0.384,Not available++Not available++Not available++Not available,1,,,
DCTPep01723,PC-3,Prostate carcinoma,Carcinoma,LD50=28 µg/ml,KTKLFKKFAKKLAKKLKKLAKKL,23,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2730.6,2728.87,11.04,CDEGHIMNPQRSVWY,K,C133H241N35O25,12,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-19.12,97.83,-0.761,Not available++Not available++Not available++Not available,1,,,
DCTPep01374,U251 ,Astrocytoma,Carcinoma,IC50=6.5±1.1μM,KLLLKLLKKLLKLLKKK,17,Synthetic,Synthetic peptide,Anticancer,ACP##Tumor active peptide##Cancer targeted peptides,2061.84,2060.53,10.85,ACDEFGHIMNPQRSTVWY,L,C102H197N25O18,8,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-30.54,206.47,0.176,Not available++Not available++Not available++Not available,1,,,
DCTPep01674,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,LD50=400 µg/ml,FAKLWAKLAKKL,12,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1416.82,1415.9,10.48,CDEGHIMNPQRSTVY,K,C71H117N17O13,4,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.882,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-4.85,122.50,0.258,Not available++Not available++Not available++Not available,1,,,
DCTPep00175,SSKT-1,Leukemia,Leukemia,IC50=107 µg/ml,ALSKALSKALSKALSKALSKALSK,24,Xenopus laevis,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide,2414.96,2413.5,10.70,CDEFGHIMNPQRTVWY,AKLS,C108H200N30O31,6,Should not be visible by UV spectrophotometry.,"4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",9.58,122.50,0.225,1708887++Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation++10.1073/pnas.88.9.3792++1990##2285300++Magainin analogs effective against pathogenic protozoa++10.1128/AAC.34.9.1824++1990,1,,,
DCTPep00284,A549,Lung adenocarcinoma,Carcinoma,IC50=7.59 µM ,GEFLKCGESCVQGECYTPGCSCDWPICKKN,30,Clitoria ternatea,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,3285.76,3283.36,4.87,AHMR,C,C138H210N36O45S6,-1,"Ext. coefficient     7365##Abs 0.1% (=1 g/l)   2.241, assuming all pairs of Cys residues form cystines##Ext. coefficient     6990##Abs 0.1% (=1 g/l)   2.127, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",43.17,35.67,-0.390,21596752++Discovery and characterization of novel cyclotides originated from chimeric precursors consisting of albumin-1 chain a and cyclotide domains in the Fabaceae family++10.1074/jbc.M111.229922++2011##23419988++Chemosensitizing activities of cyclotides from Clitoria ternatea in paclitaxel-resistant lung cancer cells++10.3892/ol.2012.1042++2013,1,,,
DCTPep00024,"RCCs (A-498, Caki-2, 786-0, 769-P, ACHN, LE 9211-RCC, TW33, N43)",Renal Cell Carcinoma,Carcinoma,"At higher concentrations than 25 μg/ml, HNPs-1, -2, and -3 exerted cytotoxic effects on all tested RCC lines in an in vitro serum-free culture system (at lower concentrations they stimulated cell grow",DCYCRIPACIAGERRYGTCIYQGRLWAFCC,30,Human alpha-defensins,Native peptide,Anticancer,ACP##Tumor active peptide##Membrane-targeted,3492.1,3489.55,8.33,HKMNSV,C,C151H228N44O40S6,2,"Ext. coefficient    10345##Abs 0.1% (=1 g/l)   2.962, assuming all pairs of Cys residues form cystines##Ext. coefficient     9970##Abs 0.1% (=1 g/l)   2.855, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",41.06,62.00,0.123,"11943716++Human alpha-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation++10.1016/s0002-9440(10)62558-8++2002",1,,,
DCTPep00002,NCI-H146,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,IC50=15.8 µM,KWKLFKKIGIGKFLHSAKKF,20,Ceropin-Magainin hybrid peptides,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2405.02,2403.47,10.78,CDEMNPQRTVY,K,C120H190N30O22,8,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.287,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-15,83.00,-0.310,"10675500++Effects of the hinge region of cecropin A(1-8)-magainin 2(1-12), a synthetic antimicrobial peptide, on liposomes, bacterial and tumor cells++10.1016/s0005-2736(99)00210-2++2000##9352466++Structure-antitumor and hemolytic activity relationships of synthetic peptides derived from cecropin A-magainin 2 and cecropin A-melittin hybrid peptides++10.1111/j.1399-3011.1997.tb01469.x++1997",1,,,
DCTPep00229,A-375,Amelanotic melanoma,Carcinoma,"86 ± 0.57% cell viability at 10 µM, 63.8 ± 0.8% cell viability at 20 µM, 47.5 ± 1.66% cell viability at 40 µM, 26.9 ± 0.5% cell viability at 60 µM, 6.5 ± 1.07% cell viability at 80 µM",KWKLFKKIPKFLHLAKKF,18,Synthetic,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,2300.95,2299.44,10.78,CDEGMNQRSTVY,K,C118H186N28O19,8,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.390,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-9.94,92.22,-0.383,19957017++Anti-melanoma activity of hybrid peptide P18 and its mechanism of action++10.1007/s10529-009-0175-2++2010,1,,,
DCTPep00361,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=32 µM,GTGLPMSERRKIMLMMR,17,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,2007.52,2006.04,11.71,ACDFHNQVWY,M,C83H151N27O22S4,3,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",66.06,68.82,-0.300,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,1,,,
DCTPep01668,BMKC,Skin carcinoma,Carcinoma,LD50=10 µg/ml,FAKLLAKLAKKVL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1442.89,1441.97,10.48,CDEGHIMNPQRSTWY,KL,C71H127N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,165.38,0.923,Not available++Not available++Not available++Not available,1,,,
DCTPep01697,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FALKALKK,8,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,918.19,917.61,10.30,CDEGHIMNPQRSTVWY,K,C45H79N11O9,3,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.48,122.50,0.287,Not available++Not available++Not available++Not available,1,,,
DCTPep02173,Human nasopharyngeal carcinoma,Nasopharyngeal carcinoma,Carcinoma,IC50=0.06 µM,PGMGIYLPM,9,Annona cherimola,Native peptide,Anticancer,ACP##Tumor active peptide,978.23,977.47,5.95,ACDEFHKNQRSTVW,GMP,C45H71N9O11S2,0,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   1.523,">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",12.48,86.67,0.756,16040066++Two cyclopeptides from the seeds of Annona cherimola++10.1016/j.phytochem.2005.06.011++2005,1,,,
DCTPep00280,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,IC50=2.6 μM,GLPVCGETCFGGTCNTPGCTCDPWPVCTRN,30,Viola abyssinica of the Ethiopian Highlands,Native peptide,Anticancer,ACP##Tumor active peptide,3089.51,3087.25,4.37,AHIKMQSY,C,C127H194N36O42S6,-1,"Ext. coefficient     5875##Abs 0.1% (=1 g/l)   1.902, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.780, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",56.17,32.33,-0.043,21434649++Cyclotides from an extreme habitat: characterization of cyclic peptides from Viola abyssinica of the Ethiopian highlands++10.1021/np100790f++2011,1,,,
DCTPep01964,U-251MG,Astrocytoma,Carcinoma,IC50=2.0 µM,FLGMIPKLIKKLIKAFK,17,Synthetic,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1988.64,1987.28,10.60,CDEHNQRSTVWY,K,C99H170N22O18S1,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-21.1,143.53,0.747,"23770440++Two peptides, TsAP-1 and TsAP-2, from the venom of the Brazilian yellow scorpion, Tityus serrulatus: evaluation of their antimicrobial and anticancer activities++10.1016/j.biochi.2013.06.003++2013",1,,,
DCTPep01717,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=1000 µg/ml,KIAKVALAKLGIGAVLKVLTTGL,23,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2277.91,2276.49,10.48,CDEFHMNPQRSWY,L,C107H197N27O26,4,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-19.97,173.91,1.287,Not available++Not available++Not available++Not available,1,,,
DCTPep01639,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=1000 µg/ml,FAKLA,5,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not available++Not available++Not available++Not available,1,,,
DCTPep01672,BMKC,Skin carcinoma,Carcinoma,LD50=205 µg/ml,FAKLLKLAAKKLL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-16.89,173.08,0.892,Not available++Not available++Not available++Not available,1,,,
DCTPep01634,PC-3,Prostate carcinoma,Carcinoma,LD50=10 µg/ml,FAKKLAKLAKKLLAL,15,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1656.17,1655.12,10.60,CDEGHIMNPQRSTVWY,KL,C81H146N20O16,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.65,156.67,0.633,Not available++Not available++Not available++Not available,1,,,
DCTPep00480,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,70% Cytotoxicity at 5 µM Approx,GIIKKIIKKIIKKIIKKI,18,Alpha-helical proteins,Synthetic peptide,Anticancer,ACP##Tumor active peptide,2118.89,2117.55,10.85,ACDEFHLMNPQRSTVWY,I,C104H200N26O19,8,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-33.01,195.00,0.494,24246647++Molecular mechanisms of anticancer action and cell selectivity of short α-helical peptides++10.1016/j.biomaterials.2013.10.082++2014,1,,,
DCTPep00016,C8166,Adult T acute lymphoblastic leukemia,Leukemia,IC50=11.4 µg/ml,GIGGKILSGLKTALKGAAKELASTYLH,27,Bombina maxima,Native peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide,2698.2,2696.56,9.83,CDFMNPQRVW,GL,C122H209N33O35,4,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.552,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-0.68,115.93,0.244,11835991++Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima++10.1016/s0196-9781(01)00641-6,1,,,
DCTPep00088,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,IC50=10 μM,GLFAVIKKVAAVIRRL,16,Amphibian skin secretions,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,1754.24,1753.15,12.02,CDEHMNPQSTWY,AV,C83H148N24O17,4,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",34.56,170.62,1.262,"12631273++nNOS inhibition, antimicrobial and anticancer activity of the amphibian skin peptide, citropin 1.1 and synthetic modifications++10.1046/j.1432-1033.2003.03462.x++2003",1,,,
DCTPep00062,MT-1,Human mammary carcinoma,Carcinoma,IC50=20 µM,PAARKAFRWAWRMLKKAA,18,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,2158.64,2157.23,12.31,CDEGHINQSTVY,A,C101H160N32O19S1,6,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   5.096,">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",38.9,55.00,-0.517,12366526++Enhanced antitumor activity and selectivity of lactoferrin-derived peptides++10.1034/j.1399-3011.2002.21008.x++2002,1,,,
DCTPep00011,Brain tumor cell (NCI),Brain tumor,Carcinoma,LC50=10 µM,GLFDIVKKVVGAFGSL,16,Southern bell frog,Native peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,1649.99,1648.96,8.59,CEHMNPQRTWY,GV,C79H128N18O20,1,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-5.94,133.75,1.175,10951191++The antibiotic and anticancer active aurein peptides from the Australian Bell Frogs Litoria aurea and Litoria raniformis the solution structure of aurein 1.2++10.1046/j.1432-1327.2000.01536.x++2000,1,,,
DCTPep00072,ACHN ,Papillary renal cell carcinoma; Papillary renal cell carcinoma,Carcinoma,IC50=2.63 µM,GVPICGETCTLGTCYTAGCSCSWPVCTRN,29,Viola arvensis (European field pansy) (Field violet),Native peptide,Anticancer,ACP##Tumor active peptide##Membrane-targeted,2983.43,2981.23,5.96,DFHKMQ,C,C122H192N34O41S6,0,"Ext. coefficient     7365##Abs 0.1% (=1 g/l)   2.469, assuming all pairs of Cys residues form cystines##Ext. coefficient     6990##Abs 0.1% (=1 g/l)   2.343, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",52.46,50.34,0.341,12477048++Cyclotides: a novel type of cytotoxic agents++10.1097/00008390-200204000-00013++2002##20580652++Isolation and characterization of cytotoxic cyclotides from Viola tricolor++10.1016/j.peptides.2010.05.004++2010##10600388++Plant cyclotides: A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif++10.1006/jmbi.1999.3383++1999,1,,,
DCTPep00853,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=24.2±1.7 μM,KWCFRVCYRGICYRRCR,17,horseshoe crab Limulus polyphemus,Native peptide,Anticancer,ACP##Tumor active peptide,2268.77,2267.1,9.93,ADEHLMNPQST,R,C99H154N34O20S4,6,"Ext. coefficient     8730##Abs 0.1% (=1 g/l)   3.848, assuming all pairs of Cys residues form cystines##Ext. coefficient     8480##Abs 0.1% (=1 g/l)   3.738, assuming all Cys residues are reduced","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",13.22,40.00,-0.518,30486233++Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III++10.3390/md16120466++2018,1,,,
DCTPep01729,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=115 µg/ml,KWKLFKKKTKLFKKFAKKLAKKL,23,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2879.75,2877.89,11.04,CDEGHIMNPQRSVY,K,C144H244N36O25,12,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.910,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-18.27,76.52,-0.922,Not available++Not available++Not available++Not available,1,,,
DCTPep00171,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,IC50=6.7μg/ml,LKCNKLVPLFYKTCPAGKNL,20,Daboia russelii (Russel's viper) (Vipera russelii),Native peptide,Anticancer,ACP##Tumor active peptide,2250.79,2249.24,9.60,DEHIMQRSW,KL,C104H172N26O25S2,4,"Ext. coefficient     1615##Abs 0.1% (=1 g/l)   0.718, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.662, assuming all Cys residues are reduced","5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",53.8,97.50,0.040,"17055549++A heat stable protein toxin (drCT-I) from the Indian Viper (Daboia russelli russelli) venom having antiproliferative, cytotoxic and apoptotic activities++10.1016/j.toxicon.2006.09.009++2006",1,,,
DCTPep00098,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,IC50=4.88±0.53 µg/ml,FLPLLAGLAANFLPTIICKISYKC,24,Skin secretions of Rana rugosa,Native peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Induce apoptosis,2610.25,2608.45,8.86,DEHMQRVW,L,C125H201N27O29S2,2,"Ext. coefficient     1615##Abs 0.1% (=1 g/l)   0.619, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.571, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",15.83,142.50,1.283,14499271++In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines++10.1016/s0196-9781(03)00194-3++2003,1,,,
DCTPep01721,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=160 µg/ml,KLALKLALKALKAAKLA,17,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1764.31,1763.21,10.60,CDEFGHIMNPQRSTVWY,AL,C84H158N22O18,5,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-20.55,172.94,0.829,Not available++Not available++Not available++Not available,1,,,
DCTPep01750,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=260 µg/ml,WALAL,5,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not available++Not available++Not available++Not available,1,,,
DCTPep01724,SW480,Colon adenocarcinoma,Carcinoma,LD50=240 µg/ml,KWKKLAKKW,9,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1215.55,1214.77,10.60,CDEFGHIMNPQRSTVY,K,C61H98N16O10,5,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   9.049,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-0.54,54.44,-1.744,Not available++Not available++Not available++Not available,1,,,
DCTPep00105,A549,Lung adenocarcinoma,Carcinoma,IC50=24.58 ± 3.24 µg/ml,FLKLLAGLLKNFA,13,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Induce apoptosis,1447.83,1446.9,10.00,CDEHIMPQRSTVWY,L,C72H118N16O15,2,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-21.92,165.38,1.269,14499271++In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines++10.1016/s0196-9781(03)00194-3++2003,1,,,
DCTPep00238,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,IC50=3.5 μM,KLCGETCFKFKCYTPGCSCSYPFCK,25,Micronesian Plant Psychotria leptothyrsa,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,2844.4,2842.21,8.64,ADHIMNQRVW,C,C126H187N29O34S6,3,"Ext. coefficient     3355##Abs 0.1% (=1 g/l)   1.180, assuming all pairs of Cys residues form cystines##Ext. coefficient     2980##Abs 0.1% (=1 g/l)   1.048, assuming all Cys residues are reduced","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",13.45,15.60,-0.060,"20575512++Isolation, characterization, and bioactivity of cyclotides from the Micronesian plant Psychotria leptothyrsa++10.1021/np9007365++2010 ",1,,,
DCTPep00292,MM96L,Melanoma,Carcinoma,IC50=1.03±0.03µM,GSIPCGESCVFIPCISAIIGCSCSSKVCYKN,31,Viola philippica,Native peptide,Anticancer,ACP##Tumor active peptide,3169.77,3167.43,7.77,DHLMQRTW,CS,C134H218N34O42S6,1,"Ext. coefficient     1865##Abs 0.1% (=1 g/l)   0.588, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.470, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",28.81,84.84,0.813,21723349++Isolation and characterization of cytotoxic cyclotides from Viola philippica++10.1016/j.peptides.2011.06.016++2011,1,,,
DCTPep00048,Hut-78,Sezary syndrome ,Lymphoma,100% Killing=10 µM,FVQWFSKFLGRIL,13,Rana temporaria,Native peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,1640.99,1639.92,11.00,ACDEHMNPTY,F,C83H121N19O16,2,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.352,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",24.05,112.31,0.823,"12133008++Temporin L: antimicrobial, haemolytic and cytotoxic activities, and effects on membrane permeabilization in lipid vesicles++10.1042/BJ20020806++2002##21319749++Structure-activity relationship, conformational and biological studies of temporin L analogues++10.1021/jm1012853++2011##32786286++A Noncytotoxic Temporin L Analogue with In Vivo Antibacterial and Antiendotoxin Activities and a Nonmembrane-Lytic Mode of Action++10.1021/acsinfecdis.0c00022++2020",1,,,
DCTPep00404,MEC,Cholangiocarcinoma; Cholangiocarcinoma,Carcinoma,24.15Inhibition ratio at 50 µg/ml,LLRHVVKILEKYL,13,Temporins family,Synthetic peptide,Anticancer,ACP##Tumor active peptide##Membrane-targeted,1624.05,1623.02,9.70,ACDFGMNPQSTW,L,C78H134N20O17,3,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.917,"5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",44.93,194.62,0.600,22641352++Designed synthetic analogs of the α-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin αvβ3 homing domain++10.1002/psc.2420++2012,1,,,
DCTPep00100,A549,Lung adenocarcinoma,Carcinoma,IC50>100 µg/ml,FAGLAANFLPTIICKISYKC,20,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,Induce apoptosis,2173.66,2172.15,8.86,DEHMQRVW,AI,C102H161N23O25S2,2,"Ext. coefficient     1615##Abs 0.1% (=1 g/l)   0.743, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.685, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",7.37,112.50,1.050,14499271++In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines++10.1016/s0196-9781(03)00194-3++2003,1,,,
DCTPep01647,PC-3,Prostate carcinoma,Carcinoma,LD50=140 µg/ml,FAKLLAKALKKFAL,14,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1562.02,1561.01,10.48,CDEGHIMNPQRSTVWY,AKL,C78H132N18O15,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-2.84,140.00,0.886,Not available++Not available++Not available++Not available,1,,,
DCTPep00299,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,50% Cell death>128 µg/ml,FFRLLFHGVHHVGKIKPRA,19,Synthetic,Synthetic peptide,Anticancer; Antibacterial; Antifungal,Cancer therapy related peptides,2259.73,2258.31,12.02,CDEMNQSTWY,FH,C109H167N33O20,7,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-21.79,97.37,0.100,21729875++The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents++10.1242/dmm.007310++2011,1,,,
DCTPep00400,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=1.2 μM,IPCGESCVWIPCISGMFGCSCKDKVCYS,28,Chassalia chartacea,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,3016.6,3014.26,6.03,AHLNQRT,C,C129H199N31O38S7,0,"Ext. coefficient     7365##Abs 0.1% (=1 g/l)   2.441, assuming all pairs of Cys residues form cystines##Ext. coefficient     6990##Abs 0.1% (=1 g/l)   2.317, assuming all Cys residues are reduced","20 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",20.91,62.50,0.607,22467870++Novel cyclotides and uncyclotides with highly shortened precursors from Chassalia chartacea and effects of methionine oxidation on bioactivities++10.1074/jbc.M111.338970++2012,1,,,
DCTPep00255,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=2 μmol/L,KWKSFLKTFKSLKKTVLHTLLKAISS,26,PeptideV13K,Synthetic peptide,Anticancer,ACP##Tumor active peptide##Membrane-targeted,3033.74,3031.83,10.78,CDEGMNPQRY,K,C145H242N36O34,8,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.813,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",3.29,105.00,-0.062,21252288++Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework++10.1158/1535-7163.MCT-10-0811++2011##15677462++Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index++10.1074/jbc.M413406200++2005,1,,,
DCTPep00288,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=1.75±0.05µM,GSIPCGESCVFIPCISSVIGCACKSKVCYKN,31,Viola philippica,Native peptide,Anticancer,ACP##Tumor active peptide,3196.84,3194.48,8.33,DHLMQRTW,C,C136H223N35O41S6,2,"Ext. coefficient     1865##Abs 0.1% (=1 g/l)   0.583, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.466, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",32.47,81.61,0.703,21723349++Isolation and characterization of cytotoxic cyclotides from Viola philippica++10.1016/j.peptides.2011.06.016++2011,1,,,
DCTPep00120,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,"rendered all the tested cancer cell lines sensitive to doses of cisplatin, adriamycin, and mitoxantrone ",GRKKRRQRRRGGWMWVTNLRTD,22,RasGAP-derived peptides,Native peptide,Anticancer,Transducing peptide##Cell-penetrating peptides,2814.28,2812.55,12.40,ACEFHIPSY,R,C119H201N49O29S1,8,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   3.909,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",123.55,30.91,-2.014,15467750++A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells++10.1038/sj.onc.1207999++2004 ,1,,,
DCTPep00129,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,No inhibition at 7 mg/kg/d,AAVPIVNLKDELLFPSWEALFSGSE,25,Human endostatin peptides,Native peptide,Anticancer; Antiangiogenesis,Cancer targeted peptides,2733.11,2731.41,4.00,CHMQRTY,L,C128H194N28O38,-3,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.012,"4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",33.62,113.20,0.432,15867360++A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity++10.1158/0008-5472.CAN-04-1833++2005,1,,,
DCTPep00380,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=18 µM,VNWKKILGKIKKVVK,15,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,1781.3,1780.18,10.70,ACDEFHMPQRSTY,K,C86H153N23O17,6,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.088,"100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-14.96,136.00,-0.187,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,1,,,
DCTPep00357,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=14±2 µM,GKWKSLLKHILK,12,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,1450.83,1449.92,10.48,ACDEFMNPQRTVY,K,C70H119N19O14,5,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.791,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",40.61,130.00,-0.417,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,1,,,
DCTPep01822,JB6,Human anaplastic large cell lymphoma,Lymphoma,"When the peptide concentration is 40μmol/L, the cell growth inhibition rate is about 0.38.",RKGWFKAMKSIAKFIAKEKLKEHL,24,Synthetics,Synthetic peptide,Anticancer,ACP##Tumor active peptide,2888.56,2886.68,10.39,CDNPQTVY,K,C136H223N37O30S1,7,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.904,"1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-5.29,77.50,-0.608,Not available++Not available++Not available++Not available,1,,,
DCTPep00091,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,IC50=10 μM,GLFKVIKKVAKVIKKL,16,Amphibian skin secretions,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,1812.4,1811.25,10.70,CDEHMNPQRSTWY,K,C89H162N22O17,6,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-31.86,158.12,0.625,"12631273++nNOS inhibition, antimicrobial and anticancer activity of the amphibian skin peptide, citropin 1.1 and synthetic modifications++10.1046/j.1432-1033.2003.03462.x++2003",1,,,
DCTPep01642,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FAKLF,5,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not available++Not available++Not available++Not available,1,,,
DCTPep01715,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,KFKKLAKKF,9,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1137.48,1136.74,10.60,CDEGHIMNPQRSTVWY,K,C57H96N14O10,5,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-17.24,54.44,-0.922,Not available++Not available++Not available++Not available,1,,,
DCTPep01598,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FAFAKIIAKIAKKII,15,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1675.18,1674.1,10.48,CDEGHLMNPQRSTVWY,I,C84H143N19O16,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.65,156.67,1.313,Not available++Not available++Not available++Not available,1,,,
DCTPep00045,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=100.0< µM,KWKLFKKIPLKKF,13,Ceropin A,Synthetic peptide,Anticancer; Antibacterial,Membrane-targeted,1704.22,1703.1,10.70,ACDEGHMNQRSTVY,K,C88H142N20O14,6,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.227,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-24.14,90.00,-0.631,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",1,,,
DCTPep00171,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,IC50=6.7μg/ml,LKCNKLVPLFYKTCPAGKNL,20,Daboia russelii (Russel's viper) (Vipera russelii),Native peptide,Anticancer,ACP##Tumor active peptide,2250.79,2249.24,9.60,DEHIMQRSW,KL,C104H172N26O25S2,4,"Ext. coefficient     1615##Abs 0.1% (=1 g/l)   0.718, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.662, assuming all Cys residues are reduced","5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",53.8,97.50,0.040,"17055549++A heat stable protein toxin (drCT-I) from the Indian Viper (Daboia russelli russelli) venom having antiproliferative, cytotoxic and apoptotic activities++10.1016/j.toxicon.2006.09.009++2006",1,,,
DCTPep00269, --, --, --,IC50 for MDM2=0.29 µM,LTFEHYWAQLTS,12,E3 ubiquitin-protein ligase,Synthetic peptide,Anticancer; Antitumor,ACP##Tumor active peptide##Cancer targeted peptides##Affect cell cycle,1495.65,1494.71,5.24,CDGIKMNPRV,LT,C71H98N16O20,0,Ext. coefficient     6990##Abs 0.1% (=1 g/l)   4.674,"5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",28.62,73.33,-0.200,21423613++mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction++10.1371/journal.pone.0017898++2011,1,,,
DCTPep01092,NCI-H128,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,IC50=2.4 µM,KWKLFAKIGIGKFLHLAKKF,20,Ceropin A-Magainin 2,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,2374,2372.46,10.70,CDEMNPQRSTVY,K,C120H189N29O21,7,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.317,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-7.48,107.50,0.205,9352466++Structure-antitumor and hemolytic activity relationships of synthetic peptides derived from cecropin A-magainin 20 and cecropin A-melittin hybrid peptides++10.1111/j.1399-3011.1997.tb01469.x++1997,1,,,
DCTPep01670,BMKC,Skin carcinoma,Carcinoma,LD50=11 µg/ml,FAKLLALALKLKL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1441.91,1440.98,10.30,CDEGHIMNPQRSTVWY,L,C72H128N16O14,3,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-23.42,203.08,1.485,Not available++Not available++Not available++Not available,1,,,
DCTPep02012,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=14±2 µM,GKWMSLLKHIWK,12,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide,1526.91,1525.86,10.30,ACDEFNPQRTVY,K,C74H115N19O14S1,4,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   7.204,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",87.98,97.50,-0.325,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,1,,,
DCTPep01743,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=17 µg/ml,VAKLLAKLAKKLL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1408.88,1407.99,10.48,CDEFGHIMNPQRSTWY,L,C68H129N17O14,4,Should not be visible by UV spectrophotometry.,"100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-10.36,195.38,1.000,Not available++Not available++Not available++Not available,1,,,
DCTPep02019,SW480,Colon adenocarcinoma,Carcinoma,IC50=44±5 µM,GMWKKILGHLIR,12,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide,1451.84,1450.86,11.17,ACDEFNPQSTVY,GIKL,C68H114N20O13S1,4,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.788,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",18.14,130.00,0.108,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,1,,,
DCTPep00266,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,75% Cytotoxicity at 0.5 µg/ml,GIGKFLKKAKKFGKAFVKILKK,22,Helical peptide with a predominance of one or more amino acids tryptophane-rich,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide,2478.2,2476.61,10.90,CDEHMNPQRSTWY,K,C122H209N31O23,9,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-6.16,93.18,-0.159,"21403917++Antitumor activity of antimicrobial peptides against U937 histiocytic cell line++Not available++2011##8573171++A novel antimicrobial peptide from Bufo bufo gargarizans++10.1006/bbrc.1996.0071++1996##24587350++Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity++10.1371/journal.pone.0090397++2014",1,,,
DCTPep00300,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,50% Cell death=128 µg/ml,FLGALIKGAIHGGRFIHGMIQNHH,24,Pseudopleuronectes americanus,Native peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2625.1,2623.41,11.00,CDEPSTVWY,G,C120H186N38O27S1,6,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",2.22,105.83,0.271,21729875++The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents++10.1242/dmm.007310++2011,1,,,
DCTPep00504,HCT 116,Colon carcinoma,Carcinoma,Cell viability >40% at 12.5μM approx,KILRGVAKKIMRTFLRRISKDILTGKK,27,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane lysis,3170.99,3168.98,12.02,CEHNPQWY,K,C143H261N45O33S1,9,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",45.43,115.56,-0.289,24962950++Host defense peptides for treatment of colorectal carcinoma - a comparative in vitro and in vivo analysis++10.18632/oncotarget.2039++2014,1,,,
DCTPep01609,BMKC,Skin carcinoma,Carcinoma,LD50=140 µg/ml,FAKKFAKKFKKFAKKFAKFAFAF,23,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2775.47,2773.64,10.90,CDEGHILMNPQRSTVWY,K,C144H212N32O24,9,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",3.03,26.09,-0.083,Not available++Not available++Not available++Not available,1,,,
DCTPep01658,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FAKLLAKLAKK,11,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1230.6,1229.82,10.48,CDEGHIMNPQRSTVWY,K,C60H107N15O12,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-6.35,133.64,0.364,Not available++Not available++Not available++Not available,1,,,
DCTPep00124,MKN7,Gastric tubular adenocarcinoma,Carcinoma,35 % Cytotoxity at 40 µg/ml,LRVRLASHLRKLRKRLLRDADDLQKRLAVY,30,Apoprotein E,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide,3673.42,3671.22,11.63,CEFGIMNPTW,L,C162H287N57O40,8,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.406,"5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",59.77,133.33,-0.610,15796184++Anti-tumor activity of an antibiotic peptide derived from apoprotein E++Not available++2005,1,,,
DCTPep01093,NCI-H146,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,IC50=1.8 µM,KWKKFLKIGIGKFLHLAKKF,20,Ceropin A-Magainin 2,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,2431.1,2429.52,10.78,CDEMNPQRSTVY,K,C123H196N30O21,8,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.262,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-7.48,102.50,-0.080,9352466++Structure-antitumor and hemolytic activity relationships of synthetic peptides derived from cecropin A-magainin 21 and cecropin A-melittin hybrid peptides++10.1111/j.1399-3011.1997.tb01469.x++1997,1,,,
DCTPep01601,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FAKAIAKIAFGKGIGKVGKKLL,22,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2258.87,2257.44,10.70,CDEHMNPQRSTWY,K,C109H188N28O23,6,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-25.19,120.00,0.595,Not available++Not available++Not available++Not available,1,,,
DCTPep00006,Brain tumor cell (NCI),Brain tumor,Carcinoma,LC50=10 µM,GLFDIAKKVIGVIGSL,16,Southern bell frog,Native peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,1630,1628.99,8.59,CEHMNPQRTWY,GI,C77H132N18O20,1,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",11.78,164.38,1.300,10951191++The antibiotic and anticancer active aurein peptides from the Australian Bell Frogs Litoria aurea and Litoria raniformis the solution structure of aurein 1.2++10.1046/j.1432-1327.2000.01536.x++2000,1,,,
DCTPep00295,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=1.32±0.15µM,GLPVCGETCVGGTCNTPGCACSWPVCTRN,29,Viola philippica,Native peptide,Anticancer,ACP##Tumor active peptide,2886.32,2884.19,5.96,DFHIKMQY,C,C116H185N35O39S6,0,"Ext. coefficient     5875##Abs 0.1% (=1 g/l)   2.035, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.906, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",50.5,46.90,0.238,21723349++Isolation and characterization of cytotoxic cyclotides from Viola philippica++10.1016/j.peptides.2011.06.016++2011,1,,,
DCTPep01964,U-251MG,Astrocytoma,Carcinoma,IC50=2.0 µM,FLGMIPKLIKKLIKAFK,17,Synthetic,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1988.64,1987.28,10.60,CDEHNQRSTVWY,K,C99H170N22O18S1,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-21.1,143.53,0.747,"23770440++Two peptides, TsAP-1 and TsAP-2, from the venom of the Brazilian yellow scorpion, Tityus serrulatus: evaluation of their antimicrobial and anticancer activities++10.1016/j.biochi.2013.06.003++2013",1,,,
DCTPep02039,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,19 ± 2.82% Inhibition=160 μM,CHHNLTHAC,9,Synthetic,Synthetic peptide,Anticancer,Cancer targeted peptides##PTPRJ agonist,1035.16,1034.42,7.00,DEFGIKMPQRSVWY,H,C41H62N16O12S2,3,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.121, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",120.24,54.44,-0.356,23627474++Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation++10.1021/cb3007192++2013,1,,,
DCTPep01237,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,50% Cytotoxicity=281 ± 56.5 μM ,RQIKIWFQNRRMKWKK,16,Antennapedia homeodomain,Native peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide##Cell-penetrating peptides,2246.75,2245.29,12.31,ACDEGHLPSTVY,K,C104H168N34O20S1,7,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   4.896,"1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",46.6,48.75,-1.731,23085001++Antimicrobial and cell-penetrating properties of penetratin analogs: effect of sequence and secondary structure++10.1016/j.bbamem.2012.10.010++2013,1,,,
DCTPep00031,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,IC50=11 µM,KWFKKIPKFLHLAKKF,16,Ceropin A,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2059.62,2058.27,10.70,CDEGMNQRSTVY,K,C106H163N25O17,7,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.670,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-7.12,79.38,-0.425,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",1,,,
DCTPep02528,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Not active up to 100μg/ml,KISKRILTGKK,11,Synthetic,Synthetic peptide,Anticancer; Antibacterial,Membrane lysis,1271.61,1270.84,11.33,ACDEFHMNPQVWY,K,C57H110N18O14,5,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",33.08,106.36,-0.836,17389605++Rationale for the design of shortened derivatives of the NK-lysin-derived antimicrobial peptide NK-2 with improved activity against Gram-negative pathogens++10.1074/jbc.M608920200++2007,1,,,
DCTPep00330,MT-1,Human mammary carcinoma,Carcinoma,EC50=28 µM,KAAKKAWKWAKKAAKWAKKAA,21,Synthetic,Synthetic peptide,Anticancer,ACP##Tumor active peptide,2369.93,2368.44,10.90,CDEFGHILMNPQRSTVY,AK,C114H185N33O22,9,Ext. coefficient    16500##Abs 0.1% (=1 g/l)   6.962,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-4.79,42.86,-1.029,22057278++Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity++10.1074/jbc.M111.279281++2012,1,,,
DCTPep02173,Human nasopharyngeal carcinoma,Nasopharyngeal carcinoma,Carcinoma,IC50=0.06 µM,PGMGIYLPM,9,Annona cherimola,Native peptide,Anticancer,ACP##Tumor active peptide,978.23,977.47,5.95,ACDEFHKNQRSTVW,GMP,C45H71N9O11S2,0,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   1.523,">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",12.48,86.67,0.756,16040066++Two cyclopeptides from the seeds of Annona cherimola++10.1016/j.phytochem.2005.06.011++2005,1,,,
DCTPep00351,SW480,Colon adenocarcinoma,Carcinoma,IC50=17±2 µM,GFGMALRLLRRVL,13,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,1501.9,1500.91,12.30,CDEHIKNPQSTWY,L,C68H120N22O14S1,3,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",92.42,150.00,0.892,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,1,,,
DCTPep00139,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,IC50=38 µM,MRKWFHNVLSSGQLLADKWPAWDYNRK,27,S. pneumoniae,Synthetic peptide,Anticancer,ACP##Tumor active peptide,3347.85,3345.7,9.99,CEIT,KLW,C155H228N44O38S1,4,Ext. coefficient    17990##Abs 0.1% (=1 g/l)   5.374,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",23.59,61.48,-0.930,16004618++Functional and structural characteristics of anticancer peptide Pep27 analogues++10.1186/1475-2867-5-21++2005,1,,,
DCTPep02046,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,20 ± 1.4% Inhibition=160 μM,CHHNLTAAC,9,Synthetic (Derived from PTPRJ pep-19),Synthetic peptide,Anticancer,Cancer targeted peptides##PTPRJ agonist,969.1,968.4,6.90,DEFGIKMPQRSVWY,ACH,C38H60N14O12S2,2,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.129, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",120.24,65.56,0.200,23627474++Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation++10.1021/cb3007192++2013,1,,,
DCTPep00170,HepG2,Hepatoblastoma,Blastoma,IC50=58 µg/ml,FLPLAVSLAANFLPKLFCKITKKC,24,Amolops loloensis; Amolops jingdongensis,Native peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2666.36,2664.53,9.70,DEGHMQRWY,L,C128H209N29O28S2,4,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.047, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",12.3,122.08,0.946,"17000029++Two families of antimicrobial peptides with multiple functions from skin of rufous-spotted torrent frog, Amolops loloensis++10.1016/j.peptides.2006.08.017++2006",1,,,
DCTPep01657,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,LD50=210 µg/ml,FAKLLAKLAKAKL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1414.84,1413.94,10.48,CDEGHIMNPQRSTVWY,AKL,C69H123N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,150.77,0.738,Not available++Not available++Not available++Not available,1,,,
DCTPep01693,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=21 µg/ml,FALALKKALKALKKAL,16,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1727.25,1726.16,10.60,CDEGHIMNPQRSTVWY,AKL,C84H151N21O17,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-6.54,153.12,0.706,Not available++Not available++Not available++Not available,1,,,
DCTPep00063,Meth A,Mouse fibrosarcoma,Sarcoma,IC50=116 µM,PAARKAARWAWRMLKKGA,18,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,2068.52,2067.18,12.31,CDEFHINQSTVY,A,C94H154N32O19S1,6,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   5.318,">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",29.47,55.00,-0.694,12366526++Enhanced antitumor activity and selectivity of lactoferrin-derived peptides++10.1034/j.1399-3011.2002.21008.x++2002,1,,,
DCTPep01602,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=23 µg/ml,FAKALAKLAKKLL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1414.84,1413.94,10.48,CDEGHIMNPQRSTVWY,AKL,C69H123N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,150.77,0.738,Not available++Not available++Not available++Not available,1,,,
DCTPep01692,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,LD50=145 µg/ml,FALALKALKKLLKKLKKLAKKAL,23,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2579.43,2577.79,10.90,CDEGHIMNPQRSTVWY,K,C126H232N32O24,9,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-16.27,157.39,0.309,Not available++Not available++Not available++Not available,1,,,
DCTPep00007,Brain tumor cell (NCI),Brain tumor,Carcinoma,LC50=10 µM,GLFDIIKKIAESF,13,Southern bell frog,Native peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,1480.77,1479.83,6.07,CHMNPQRTVWY,I,C71H113N15O19,0,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",20.48,127.69,0.669,10951191++The antibiotic and anticancer active aurein peptides from the Australian Bell Frogs Litoria aurea and Litoria raniformis the solution structure of aurein 1.2++10.1046/j.1432-1327.2000.01536.x++2000,1,,,
DCTPep00249,NCI-H1299,Lung large cell carcinoma,Carcinoma,IC50=16.4 μmol/L,KWKSFLKTFKSAKKTVAHTALKAISS,26,PeptideV13K,Synthetic peptide,Anticancer,ACP##Tumor active peptide##Membrane-targeted,2907.5,2905.69,10.78,CDEGMNPQRY,K,C136H224N36O34,8,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.892,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",3.29,71.54,-0.292,21252288++Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework++10.1158/1535-7163.MCT-10-0811++2011##15677462++Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index++10.1074/jbc.M413406200++2005,1,,,
DCTPep00292,MM96L,Melanoma,Carcinoma,IC50=1.03±0.03µM,GSIPCGESCVFIPCISAIIGCSCSSKVCYKN,31,Viola philippica,Native peptide,Anticancer,ACP##Tumor active peptide,3169.77,3167.43,7.77,DHLMQRTW,CS,C134H218N34O42S6,1,"Ext. coefficient     1865##Abs 0.1% (=1 g/l)   0.588, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.470, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",28.81,84.84,0.813,21723349++Isolation and characterization of cytotoxic cyclotides from Viola philippica++10.1016/j.peptides.2011.06.016++2011,1,,,
DCTPep01607,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FAKIIAKIAKKI,12,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1343.76,1342.91,10.48,CDEGHLMNPQRSTVWY,IK,C66H118N16O13,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.06,155.00,0.883,Not available++Not available++Not available++Not available,1,,,
DCTPep01742,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=45 µg/ml,VAKLLAKALKKLL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1408.88,1407.99,10.48,CDEFGHIMNPQRSTWY,L,C68H129N17O14,4,Should not be visible by UV spectrophotometry.,"100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-10.36,195.38,1.000,Not available++Not available++Not available++Not available,1,,,
DCTPep00029,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=12 µM,WKLFKKIPKFLHLAKKF,17,Ceropin A,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2172.78,2171.35,10.70,CDEGMNQRSTVY,K,C112H174N26O18,7,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.531,"2.8 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-11.11,97.65,-0.176,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",1,,,
DCTPep00344,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=10±4 µM,GFGMALKLLKKVL,13,Macropins and their analogs,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,1417.86,1416.89,10.30,CDEHINPQRSTWY,L,C68H120N16O14S1,3,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-7.4,150.00,1.031,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,1,,,
DCTPep00251,NCI-H1299,Lung large cell carcinoma,Carcinoma,IC50=14 μmol/L,KWKSFAKTFKSAKKTVLHTALKAISS,26,PeptideV13K,Synthetic peptide,Anticancer,ACP##Tumor active peptide##Membrane-targeted,2907.5,2905.69,10.78,CDEGMNPQRY,K,C136H224N36O34,8,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.892,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",9.82,71.54,-0.292,21252288++Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework++10.1158/1535-7163.MCT-10-0811++2011##15677462++Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index++10.1074/jbc.M413406200++2005,1,,,
DCTPep00175,SSKT-1,Leukemia,Leukemia,IC50=107 µg/ml,ALSKALSKALSKALSKALSKALSK,24,Xenopus laevis,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide,2414.96,2413.5,10.70,CDEFGHIMNPQRTVWY,AKLS,C108H200N30O31,6,Should not be visible by UV spectrophotometry.,"4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",9.58,122.50,0.225,1708887++Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation++10.1073/pnas.88.9.3792++1990##2285300++Magainin analogs effective against pathogenic protozoa++10.1128/AAC.34.9.1824++1990,1,,,
DCTPep00107,N202.A2,Spontaneous tumor in A2×neu mice, -- ,"Animals immunized three times with DC pulsed with p369–377 or p773–782 peptide showed ~25–30% tumor growth inhibition, while two immunizations induced ~12–15% tumor growth inhibition and one injection",KIFGSLAFL,9,Synthetic,Synthetic peptide,Anticancer,ACP##Tumor active peptide##Immune system stimulating peptides,995.23,994.59,8.75,CDEHMNPQRTVWY,FL,C50H78N10O11,1,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-0.54,141.11,1.600,14991605++The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity++10.1002/eji.200324427++2004,1,,,
DCTPep00395,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=9.8 μM,GASCGETCFTGICFTAGCSCNPWPTCTRN,29,Chassalia chartacea,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2988.36,2986.16,5.96,DHKLMQVY,C,C122H183N35O41S6,0,"Ext. coefficient     5875##Abs 0.1% (=1 g/l)   1.966, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.840, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",34.27,20.34,0.100,22467870++Novel cyclotides and uncyclotides with highly shortened precursors from Chassalia chartacea and effects of methionine oxidation on bioactivities++10.1074/jbc.M111.338970++2012,1,,,
DCTPep00140,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,IC50=29 µM,MWKEFHNVLSSGQLLADKRWARWYNRW,27,S. pneumoniae,Synthetic peptide,Anticancer,ACP##Tumor active peptide,3478.98,3476.75,10.27,CIPT,W,C162H233N47O38S1,4,Ext. coefficient    23490##Abs 0.1% (=1 g/l)   6.752,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",89.4,61.48,-0.926,16004618++Functional and structural characteristics of anticancer peptide Pep27 analogues++10.1186/1475-2867-5-21++2005,1,,,
DCTPep01091,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,IC50=1.7 µM,KWKLFKKIGIGKFKLAKKF,19,Ceropin A-Magainin 2,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,2308.97,2307.47,10.85,CDEHMNPQRSTVY,K,C117H190N28O20,8,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.382,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-28.69,87.37,-0.321,9352466++Structure-antitumor and hemolytic activity relationships of synthetic peptides derived from cecropin A-magainin 19 and cecropin A-melittin hybrid peptides++10.1111/j.1399-3011.1997.tb01469.x++1997,1,,,
DCTPep00060,Meth A,Mouse fibrosarcoma,Sarcoma,IC50=110 µM,PAWAKAFRAAARMKLKAA,18,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,1958.4,1957.12,12.02,CDEGHINQSTVY,A,C90H148N28O19S1,5,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.808,">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",2.36,66.11,-0.017,12366526++Enhanced antitumor activity and selectivity of lactoferrin-derived peptides++10.1034/j.1399-3011.2002.21008.x++2002,1,,,
DCTPep01718,PC-3,Prostate carcinoma,Carcinoma,LD50=1000 µg/ml,KKVVFKVKFK,10,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1250.64,1249.83,10.60,ACDEGHILMNPQRSTWY,K,C63H107N15O11,5,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-40.92,87.00,-0.130,Not available++Not available++Not available++Not available,1,,,
DCTPep01663,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FAKLLAKLAKKGL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1400.81,1399.93,10.48,CDEHIMNPQRSTVWY,KL,C68H121N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,143.08,0.569,Not available++Not available++Not available++Not available,1,,,
DCTPep01605,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FAKGVGKVGKKAL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1302.63,1301.82,10.48,CDEHIMNPQRSTWY,K,C61H107N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-29.95,90.00,0.138,Not available++Not available++Not available++Not available,1,,,
DCTPep00136,M1,Mouse myeloid leukemia ,Leukemia,70%Inhibition=0.5mg/ml,KTCENLADTY,10,Ground beans,Native peptide,Anticancer,ACP##Tumor active peptide,1157.26,1156.51,4.37,FGHIMPQRSVW,T,C48H76N12O19S1,-1,"Ext. coefficient     1490##Abs 0.1% (=1 g/l)   1.288, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   1.288, assuming all Cys residues are reduced","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-14.52,49.00,-0.900,"15949629++Sesquin, a potent defensin-like antimicrobial peptide from ground beans with inhibitory activities toward tumor cells and HIV-1 reverse transcriptase++10.1016/j.peptides.2005.01.003++2005",1,,,
DCTPep00360,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=14±2 µM,GMWSKLLGHLLR,12,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,1410.74,1409.8,11.00,ACDEFINPQTVY,L,C65H107N19O14S1,3,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.899,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",18.14,130.00,0.250,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,1,,,
DCTPep01678,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FALAKKALKKAKKAL,15,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1629.11,1628.09,10.70,CDEGHIMNPQRSTVWY,K,C78H141N21O16,6,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",3.67,111.33,-0.013,Not available++Not available++Not available++Not available,1,,,
DCTPep00043,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=100.0< µM,KWKLFKKIPLAKKF,14,Ceropin A,Synthetic peptide,Anticancer; Antibacterial,Membrane-targeted,1775.3,1774.14,10.70,CDEGHMNQRSTVY,K,C91H147N21O15,6,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.098,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-15.64,90.71,-0.457,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",1,,,
DCTPep00445,MDA-MB-231,Breast adenocarcinoma,Carcinoma,IC50=10 µM,RRRRRWCMNW,10,Nullomer derived anticancer peptides (NulloPs):,Native peptide,Anticancer,ACP##Tumor active peptide,1519.81,1518.77,12.18,ADEFGHIKLPQSTVY,R,C64H102N28O12S2,5,"Ext. coefficient    11000##Abs 0.1% (=1 g/l)   7.238, assuming all pairs of Cys residues form cystines##Ext. coefficient    11000##Abs 0.1% (=1 g/l)   7.238, assuming all Cys residues are reduced","1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",317.63,0.00,-2.340,23000474++Nullomer derived anticancer peptides (NulloPs): differential lethal effects on normal and cancer cells in vitro++10.1016/j.peptides.2012.09.015++2012,1,,,
DCTPep00028,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,IC50=3 µM,KWKLFKKISKFLHLAKKF,18,Ceropin A,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2290.91,2289.42,10.78,CDEGMNPQRTVY,K,C116H184N28O20,8,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.401,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-8.34,92.22,-0.339,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",1,,,
DCTPep00154,KBv,Human oral carcinoma,Carcinoma,LC50=25±1 µM,FKRIVQRIKDFLRNLV,16,"LL-37,a series of peptide fragments",Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Induce apoptosis,2045.51,2044.24,11.72,ACEGHMPSTWY,R,C95H161N29O21,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",24.78,133.75,-0.075,16637646++Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region++10.1021/ja0584875++2005,1,,,
DCTPep01730,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=110 µg/ml,KYKKALKKLAKLL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1545.03,1544.05,10.40,CDEFGHIMNPQRSTVW,K,C75H137N19O15,6,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.964,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-10.36,135.38,-0.454,Not available++Not available++Not available++Not available,1,,,
DCTPep00310,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,50% Cell death=64 µg/ml,GWRTLLKKAEVKTVGKLALKHYL,23,Synthetic,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2653.25,2651.6,10.30,CDFIMNPQS,KL,C125H210N34O29,6,Ext. coefficient     6990##Abs 0.1% (=1 g/l)   2.635,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",14.33,118.70,-0.178,21729875++The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents++10.1242/dmm.007310++2011,1,,,
DCTPep01749,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=84 µg/ml,VALALKALKKLAKKLKKLAKKAL,23,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2489.3,2487.74,10.90,CDEFGHIMNPQRSTWY,K,C119H226N32O24,9,Should not be visible by UV spectrophotometry.,"100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-12.58,157.39,0.283,Not available++Not available++Not available++Not available,1,,,
DCTPep00442,A549,Lung adenocarcinoma,Carcinoma,IC50=28 µM,FLGALFHALSKLL,13,Synthetic,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane lysis,1429.77,1428.85,8.76,CDEIMNPQRTVWY,L,C71H112N16O15,2,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,165.38,1.531,22934601++Peptide Self-Assembly on Cell Membranes to Induce Cell Lysis++10.1021/bm301106p++2012##22526264++Activity and selectivity of histidine-containing lytic peptides to antibiotic-resistant bacteria++10.1007/s00203-012-0810-5++2012,1,,,
DCTPep01613,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,LD50=260 µg/ml,FAKKLAKKLAKAL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1429.86,1428.95,10.60,CDEGHIMNPQRSTVWY,K,C69H124N18O14,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,120.77,0.146,Not available++Not available++Not available++Not available,1,,,
DCTPep00806,U-251MG,Astrocytoma,Carcinoma,IC50=25.13µM,FLPIVAKLLSGLL,13,Pelophylax kl.esculentus(Europe edible frog),Native peptide,Anticancer; Antimicrobial; Antibacterial; Anitifungal,ACP##Tumor active peptide##Membrane-targeted,1383.78,1382.89,8.75,CDEHMNQRTWY,L,C69H118N14O15,1,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",10.98,210.00,1.969,"29191658++Identification and target-modifications of temporin-PE: A novel antimicrobial peptide in the defensive skin secretions of the edible frog, Pelophylax kl. Esculentus++10.1016/j.bbrc.2017.11.173++2017",1,,,
DCTPep00205,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,LD50=12 μM,FLPAIVGAAAKFLPKIFCAISKKC,24,"North America, leopard frog, Lithobates blairi",Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane lysis,2537.21,2535.45,9.70,DEHMNQRTWY,A,C122H198N28O26S2,4,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.049, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",19.51,114.17,1.154,"19254736++Peptides with potent cytolytic activity from the skin secretions of the North American leopard frogs, Lithobates blairi and Lithobates yavapaiensis++10.1016/j.toxicon.2009.02.018++2009",1,,,
DCTPep00467,NCI-H838,Lung adenocarcinoma,Carcinoma,IC50=52.5μM,FLSLIPSLVGGSISAFK,17,Tityus serrulatus (Brazilian yellow scorpion),Native peptide,Anticance; Antimicrobial; Antibacterial,ACP##Tumor active peptide,1736.08,1734.99,8.75,CDEHMNQRTWY,S,C83H134N18O22,1,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",12.47,137.65,1.324,"23770440++Two peptides, TsAP-1 and TsAP-2, from the venom of the Brazilian yellow scorpion, Tityus serrulatus: evaluation of their antimicrobial and anticancer activities++10.1016/j.biochi.2013.06.003++2013",1,,,
DCTPep00124,MKN7,Gastric tubular adenocarcinoma,Carcinoma,35 % Cytotoxity at 40 µg/ml,LRVRLASHLRKLRKRLLRDADDLQKRLAVY,30,Apoprotein E,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide,3673.42,3671.22,11.63,CEFGIMNPTW,L,C162H287N57O40,8,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.406,"5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",59.77,133.33,-0.610,15796184++Anti-tumor activity of an antibiotic peptide derived from apoprotein E++Not available++2005,1,,,
DCTPep00361,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=32 µM,GTGLPMSERRKIMLMMR,17,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,2007.52,2006.04,11.71,ACDFHNQVWY,M,C83H151N27O22S4,3,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",66.06,68.82,-0.300,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,1,,,
DCTPep00332,MT-1,Human mammary carcinoma,Carcinoma,EC50=173 µM,KAAKKWAKAWKKAAKAWKKAA,21,Synthetic,Synthetic peptide,Anticancer,ACP##Tumor active peptide,2369.93,2368.44,10.90,CDEFGHILMNPQRSTVY,AK,C114H185N33O22,9,Ext. coefficient    16500##Abs 0.1% (=1 g/l)   6.962,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",2.37,42.86,-1.029,22057278++Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity++10.1074/jbc.M111.279281++2012,1,,,
DCTPep02801,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,IC50=15.5 ± 0.3 μM,RFRLPFRRPPIRIHPPPFYPPFRRFL,26,Capra hircus,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Induce apoptosis,3377.1,3374.94,12.40,ACDEGKMNQSTVW,P,C166H247N49O28,8,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.441,"1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",141.27,60.00,-0.700,33194795++Caprine Bactenecins as Promising Tools for Developing New Antimicrobial and Antitumor Drugs++10.3389/fcimb.2020.552905++2020,1,,,
DCTPep00273, --, --, --,IC50 for MDM2>100 µM,PRFWEAWLRLME,12,E3 ubiquitin-protein ligase,Synthetic peptide,Anticancer; Antitumor,Cancer targeted peptides##Affect cell cycle,1633.93,1632.82,6.57,CDGHIKNQSTVY,ELRW,C78H112N20O17S1,0,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   6.732,">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",29.22,73.33,-0.442,21423613++mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction++10.1371/journal.pone.0017898++2011,1,,,
DCTPep00390,SW480,Colon adenocarcinoma,Carcinoma,IC50=30 µM,VYWKKILGKIIKVVK,15,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,1815.36,1814.19,10.30,ACDEFHMNPQRST,K,C91H155N21O17,5,Ext. coefficient     6990##Abs 0.1% (=1 g/l)   3.850,"100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-19.99,162.00,0.520,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,1,,,
DCTPep00576,A549,Lung adenocarcinoma,Carcinoma,28% Inhibition=5µM(In a cell invasion assay); 56% Inhibition=50µM(In a cell invasion assay),GFGSKPLDSFGLNFF,15,Streptomyces leeuwenhoekii,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,1632.84,1631.8,5.84,ACEHIMQRTVWY,F,C79H109N17O21,0,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",7.13,52.00,0.233,"26402731++Chaxapeptin, a Lasso Peptide from Extremotolerant Streptomyces leeuwenhoekii Strain C58 from the Hyperarid Atacama Desert++10.1021/acs.joc.5b01878++2015",1,,,
DCTPep00237,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,IC50=0.76 μM,GVIPCGESCVFIPCISSVLGCSCKNKVCYRD,31,Micronesian Plant Psychotria leptothyrsa,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,3280.91,3278.51,7.77,AHMQTW,C,C139H227N37O42S6,1,"Ext. coefficient     1865##Abs 0.1% (=1 g/l)   0.568, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.454, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",30.99,87.74,0.652,"20575512++Isolation, characterization, and bioactivity of cyclotides from the Micronesian plant Psychotria leptothyrsa++10.1021/np9007365++2010 ",1,,,
DCTPep02014,SW480,Colon adenocarcinoma,Carcinoma,IC50=38±6 µM,GKWMSLLKKILK,12,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide,1444.89,1443.9,10.48,ACDEFHNPQRTVY,K,C69H121N17O14S1,4,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.807,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",53.27,130.00,0.008,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,1,,,
DCTPep01627,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=130 µg/ml,FAKKLAKLAKKALAL,15,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1614.09,1613.08,10.60,CDEGHIMNPQRSTVWY,AK,C78H140N20O16,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-1.99,137.33,0.500,Not available++Not available++Not available++Not available,1,,,
DCTPep00048,Hut-78,Sezary syndrome ,Lymphoma,100% Killing=10 µM,FVQWFSKFLGRIL,13,Rana temporaria,Native peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,1640.99,1639.92,11.00,ACDEHMNPTY,F,C83H121N19O16,2,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.352,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",24.05,112.31,0.823,"12133008++Temporin L: antimicrobial, haemolytic and cytotoxic activities, and effects on membrane permeabilization in lipid vesicles++10.1042/BJ20020806++2002##21319749++Structure-activity relationship, conformational and biological studies of temporin L analogues++10.1021/jm1012853++2011##32786286++A Noncytotoxic Temporin L Analogue with In Vivo Antibacterial and Antiendotoxin Activities and a Nonmembrane-Lytic Mode of Action++10.1021/acsinfecdis.0c00022++2020",1,,,
DCTPep01748,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=1000 µg/ml,VALALKALKKL,11,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1167.54,1166.81,10.30,CDEFGHIMNPQRSTWY,L,C56H106N14O12,3,Should not be visible by UV spectrophotometry.,"100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-14.06,195.45,1.191,Not available++Not available++Not available++Not available,1,,,
DCTPep02043,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,48.0 ± 2.82% Inhibition=160 μM,CHHALTHAC,9,Synthetic (Derived from PTPRJ pep-19),Synthetic peptide,Anticancer,ACP##Tumor active peptide##Cancer targeted peptides##PTPRJ agonist,992.14,991.41,7.00,DEFGIKMNPQRSVWY,H,C40H61N15O11S2,3,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.126, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",93.93,65.56,0.233,23627474++Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation++10.1021/cb3007192++2013,1,,,
DCTPep00010,Brain tumor cell (NCI),Brain tumor,Carcinoma,LC50=10 µM,GLFDIVKKIAGHIVSSI,17,Southern bell frog,Native peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,1797.17,1796.06,8.60,CEMNPQRTWY,I,C84H141N21O22,2,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",37.17,154.71,1.053,10951191++The antibiotic and anticancer active aurein peptides from the Australian Bell Frogs Litoria aurea and Litoria raniformis the solution structure of aurein 1.2++10.1046/j.1432-1327.2000.01536.x++2000,1,,,
DCTPep00018,C8166,Adult T acute lymphoblastic leukemia,Leukemia,IC50=34.4 µg/ml,SIGAKILGGVKTFFKGALKELASTYLQ,27,Bombina maxima,Native peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide,2841.39,2839.62,9.82,CDHMNPRW,GKL,C133H218N32O36,3,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.524,"1.9 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",15.62,108.52,0.404,11835991++Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima++10.1016/s0196-9781(01)00641-6,1,,,
DCTPep00372,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=4±1 µM,VNWKKIILGKIIKVVK,16,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,1879.45,1878.25,10.60,ACDEFHMPQRSTY,K,C92H163N23O18,5,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.926,"100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-13.4,176.25,0.631,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,1,,,
DCTPep01081,A549,Lung adenocarcinoma,Carcinoma,IC50=10 µM,GIGKFLKKAKKFAKAFVKIINN,22,African clawed frog Xenopus laevis skin,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,2464.08,2462.53,10.78,CDEHMPQRSTWY,K,C119H199N31O25,7,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-7.2,97.73,0.009,8319212++Anticancer efficacy of Magainin2 and analogue peptides++Not available++1993,1,,,
DCTPep00088,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,IC50=10 μM,GLFAVIKKVAAVIRRL,16,Amphibian skin secretions,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,1754.24,1753.15,12.02,CDEHMNPQSTWY,AV,C83H148N24O17,4,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",34.56,170.62,1.262,"12631273++nNOS inhibition, antimicrobial and anticancer activity of the amphibian skin peptide, citropin 1.1 and synthetic modifications++10.1046/j.1432-1033.2003.03462.x++2003",1,,,
DCTPep01637,BMKC,Skin carcinoma,Carcinoma,LD50=150 µg/ml,FAKKLKKLAKLAKKL,15,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1728.28,1727.19,10.78,CDEGHIMNPQRSTVWY,K,C84H154N22O16,7,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-18.97,124.00,-0.260,Not available++Not available++Not available++Not available,1,,,
DCTPep02045,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,19 ± 4.2% Inhibition=160 μM,CHHNLAHAC,9,Synthetic (Derived from PTPRJ pep-19),Synthetic peptide,Anticancer,Cancer targeted peptides##PTPRJ agonist,1005.14,1004.41,7.00,DEFGIKMPQRSTVWY,H,C40H60N16O11S2,3,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.124, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",110.81,65.56,-0.078,23627474++Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation++10.1021/cb3007192++2013,1,,,
DCTPep00043,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=100.0< µM,KWKLFKKIPLAKKF,14,Ceropin A,Synthetic peptide,Anticancer; Antibacterial,Membrane-targeted,1775.3,1774.14,10.70,CDEGHMNQRSTVY,K,C91H147N21O15,6,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.098,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-15.64,90.71,-0.457,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",1,,,
DCTPep01671,BMKC,Skin carcinoma,Carcinoma,LD50=445 µg/ml,FAKLLFKALKKAL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1490.94,1489.97,10.48,CDEGHIMNPQRSTVWY,KL,C75H127N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-15.39,143.08,0.815,Not available++Not available++Not available++Not available,1,,,
DCTPep00203,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,100% Cytotoxicity=75μM,ETFSDLWKLL,10,Antennapedia,Native peptide,Anticancer,ACP##Tumor active peptide,1251.44,1250.65,4.37,ACGHIMNPQRVY,L,C60H90N12O17,-1,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   4.395,"1 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",36.53,117.00,0.090,18931881++The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells++10.1245/s10434-008-0147-0++2008,1,,,
DCTPep00364,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=9 µM,KNWKKILGKIIKVVK,15,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,1795.33,1794.2,10.70,ACDEFHMPQRSTY,K,C87H155N23O17,6,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.064,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-14.96,142.67,-0.167,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,1,,,
DCTPep01076,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,IC50=28.7 µM,MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG,38,Magainin,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,4243.1,4240.46,12.13,CEHNSTY,R,C189H322N64O45S1,7,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.296,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",61.74,107.89,-0.097,7849420++Preliminary experimental anticancer activity of cecropins++Not available++1994,1,,,
DCTPep00334,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,~70% Cytotoxicity=25 mg/L,GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE,33,Red Sea Mosessole,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,3323.88,3321.82,8.59,CDHMNRWY,S,C154H248N36O45,1,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",39.52,112.42,0.745,"22073006++Pardaxin, an antimicrobial peptide, triggers caspase-dependent and ROS-mediated apoptosis in HT-1080 cells++10.3390/md9101995++2011##23598079++Truncated antimicrobial peptides from marine organisms retain anticancer activity and antibacterial activity against multidrug-resistant Staphylococcus aureus++10.1016/j.peptides.2013.04.004++2013",1,,,
DCTPep01666,PC-3,Prostate carcinoma,Carcinoma,LD50=12 µg/ml,FAKLLAKLAKKLL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,173.08,0.892,Not available++Not available++Not available++Not available,1,,,
DCTPep00020,ME-180,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,100% Cytotoxicity=200 µg/ml,KNLRRIIRKIIHIIKKYG,18,Synthetic,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,2262.86,2261.47,11.75,ACDEFMPQSTVW,I,C105H188N34O21,8,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.658,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",69.08,151.67,-0.372,11932493++Impact of single-residue mutations on the structure and function of ovispirin/novispirin antimicrobial peptides++10.1093/protein/15.3.225++2002,0,ovispirin-1,Free,Free
DCTPep00021,A549,Lung adenocarcinoma,Carcinoma,81.5% Cytotoxicity=200 µg/ml,KNLRRITRKIIHIIKKYG,18,Synthetic,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2250.81,2249.43,11.75,ACDEFMPQSVW,I,C103H184N34O22,8,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.662,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",69.08,130.00,-0.661,11932493++Impact of single-residue mutations on the structure and function of ovispirin/novispirin antimicrobial peptides++10.1093/protein/15.3.225++2002,0,novispirin T-7,Free,Free
DCTPep00109,L1210,Mouse leukemia,Leukemia,IC50=0.1 µM,DNGEAGRAAR,10,Pleurotus sajor-caju,Native peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide##Affect cell cycle,1016.04,1015.48,6.07,CFHIKLMPQSTVWY,A,C38H65N17O16,0,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-13.57,30.00,-1.490,"15003351++A ribonuclease with antimicrobial, antimitogenic and antiproliferative activities from the edible mushroom Pleurotus sajor-caju++10.1016/j.peptides.2003.11.012++2004",0,P. sajor-caju Rnase,Free,Free
DCTPep00117,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,IC50=45 µM,CFKFKFKFGSGFKFKFKFC,19,Synthetic,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2371.93,2370.22,10.05,ADEHILMNPQRTVWY,F,C121H167N25O21S2,6,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.053, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-37.99,0.00,0.126,15328096++De novo design of potent antimicrobial peptides++10.1128/AAC.48.9.3349-3357.2004++2004,0,V6,Acetylization,Amidation
DCTPep00214,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,IC50>200 µM,SAVGRHGRRFGLRKHRKH,18,"skin of the Chinese brown frog, Rana chensinensis",Native peptide,Anticancer,Cancer therapy related peptides,2155.51,2154.24,12.60,CDEIMNPQTWY,R,C92H155N41O20,10,Should not be visible by UV spectrophotometry.,"1.9 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",52.19,43.33,-1.628,"19341344++Molecular cloning of cDNAs encoding antimicrobial peptide precursors from the skin of the Chinese brown frog, Rana chensinensis++10.2108/zsj.26.220++2009",0,Chensinin-1,Free,Amidation
DCTPep00448,HT-29,Colon adenocarcinoma,Carcinoma,IC50=132±12µM ,RWRWRW,6,Synthetic,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1045.22,1044.55,12.30,ACDEFGHIKLMNPQSTVY,RW,C51H68N18O7,3,Ext. coefficient    16500##Abs 0.1% (=1 g/l)  15.786,"1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",294.73,0.00,-2.700,23209509++Modulating the activity of short arginine-tryptophan containing antibacterial peptides with N-terminal metallocenoyl groups++10.3762/bjoc.8.200++2012##17145799++Length effects in antimicrobial peptides of the (RW)n series++10.1128/AAC.00828-06++2007,0,(RW)3,Free,Amidation
DCTPep00474,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50>50 µM,RRWRIVVIRVRR,12,Synthetic,Synthetic peptide,Anticancer; Antibacterial; Antifungal,Cancer therapy related peptides,1665.07,1664.07,12.70,ACDEFGHKLMNPQSTY,R,C74H133N31O13,6,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.303,"1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",145.29,137.50,-0.525,24038773++The antimicrobial activity of Sub3 is dependent on membrane binding and cell-penetrating ability++10.1002/cbic.201300274++2013,0,Bac2a [L2R][A3W][A11R],Free,Amidation
DCTPep00503,HepG2,Hepatoblastoma,Blastoma,50% Cell death=52.51±3.6 µM,SMWSGMWRRKLKKLRNALKKKLKGE,25,Lachesana tarabaevi,Native peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,3073.8,3071.78,11.77,CDFHIPQTVY,K,C138H238N44O31S2,9,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   3.579,"1.9 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",18.36,66.40,-1.248,"24885331++Identification of natural antimicrobial agents to treat dengue infection: In vitro analysis of latarcin peptide activity against dengue virus++10.1186/1471-2180-14-140++2014##16735513++Latarcins, antimicrobial and cytolytic peptides from the venom of the spider Lachesana tarabaevi (Zodariidae) that exemplify biomolecular diversity++10.1074/jbc.M602168200++2006##34576320++Membrane Interactions of Latarcins: Antimicrobial Peptides from Spider Venom++10.3390/ijms221810156++2021",0,Latarcin-1,Free,Free
DCTPep00741,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,IC50=8.7µM,GGTIFDCGESCFLGTCYTKGCSCGEWKLCYGTN,33,Viola odorata,Native peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,3504.96,3502.41,4.68,AHMPQRV,G,C149H219N37O49S6,-1,"Ext. coefficient     8855##Abs 0.1% (=1 g/l)   2.526, assuming all pairs of Cys residues form cystines##Ext. coefficient     8480##Abs 0.1% (=1 g/l)   2.419, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",11.08,35.45,0.006,28669767++Bactericidal activity of cyclotides where phosphatidylethanolamine-lipid selectivity determines antimicrobial spectra++10.1016/j.bbamem.2017.06.018++2017,0,Tricyclon-A,Free,Free
DCTPep00792,MDA-MB-231,Breast adenocarcinoma,Carcinoma,IC50>102 μM,FKARRWQWRMKKLGA,15,Bovine Lactoferricin,Native peptide,Anticancer; Antitumor; Antimicrobial,Cancer therapy related peptides,1962.4,1961.1,12.31,CDEHINPSTVY,KR,C91H144N30O17S1,6,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   5.605,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",64.37,39.33,-1.253,28961215++Antibacterial Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Cytotoxic Effect against MDA-MB-468 and MDA-MB-231 Breast Cancer Cell Lines++10.3390/molecules22101641++2017,0,LfcinB (17-31),Free,Free
DCTPep00828,NCI-H157,Lung squamous cell carcinoma,Carcinoma,IC50=15.67 μM,ALWKDILKNAGKAALNEINQIVQ,23,skin secretion of Phyllomedusa sauvagii,Native peptide,Anticancer; Antitumor; Antimicrobial,ACP##Tumor active peptide,2550.98,2549.43,8.54,CFHMPRSTY,A,C115H192N32O33,1,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.156,"4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",22.26,131.74,-0.052,"30087268++Biological Activities of Cationicity-Enhanced and Hydrophobicity-Optimized Analogues of an Antimicrobial Peptide, Dermaseptin-PS3, from the Skin Secretion of Phyllomedusa sauvagii++10.3390/toxins10080320++2018",0,DPS3,Free,Free
DCTPep00852,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=13.7±1.3 μM,KWCFRVCYRGICYRKCR,17,horseshoe crab Limulus polyphemus,Native peptide,Anticancer,ACP##Tumor active peptide,2240.75,2239.09,9.79,ADEHLMNPQST,CR,C99H154N32O20S4,6,"Ext. coefficient     8730##Abs 0.1% (=1 g/l)   3.896, assuming all pairs of Cys residues form cystines##Ext. coefficient     8480##Abs 0.1% (=1 g/l)   3.784, assuming all Cys residues are reduced","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-20.47,40.00,-0.482,30486233++Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III++10.3390/md16120466++2018,0,TP III,Free,Free
DCTPep00855,A549,Lung adenocarcinoma,Carcinoma,IC50=10.8±1.9 μM,RRWCFRVCYKGFCYRKCR,18,horseshoe crab Limulus polyphemus,Native peptide,Anticancer,ACP##Tumor active peptide,2430.96,2429.18,10.10,ADEHILMNPQST,R,C108H164N36O21S4,7,"Ext. coefficient     8730##Abs 0.1% (=1 g/l)   3.591, assuming all pairs of Cys residues form cystines##Ext. coefficient     8480##Abs 0.1% (=1 g/l)   3.488, assuming all Cys residues are reduced","1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",58.98,16.11,-0.800,30486233++Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III++10.3390/md16120466++2018,0,PM II,Free,Free
DCTPep02174,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=35 µM,RIIDLLWRVRRPQKPKFVTVWVR,23,Sus scrofa,Native peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide,2962.63,2960.78,12.18,ACEGHMNSY,R,C140H229N43O28,6,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   3.713,"1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",50.85,118.26,-0.296,"12054589++Design of novel peptide analogs with potent fungicidal activity, based on PMAP-23 antimicrobial peptide isolated from porcine myeloid++10.1016/S0006-291X(02)00222-X++2002##20512598++C-terminal amidation of PMAP-23: translocation to the inner membrane of Gram-negative bacteria++10.1007/s00726-010-0632-1++2011",0,"PMAP-23, Myeloid antibacterial peptide 23",Free,Amidation
DCTPep02256,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,IC50=132.3 µM,RRWKIVVIRWRR,12,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide,1724.14,1723.07,12.60,ACDEFGHLMNPQSTY,R,C80H134N30O13,6,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   6.380,"1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",185.95,113.33,-0.900,23478953++Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides++10.1128/AAC.00175-13++2013,0,PL-D 38,Free,Free
DCTPep02285,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,LC50=50 μM,FLPLLASLFSRLF,13,Rana ornativentris,Native peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide##Membrane lysis,1523.88,1522.89,9.75,CDEGHIKMNQTVWY,L,C77H118N16O16,1,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",38.86,157.69,1.654,"29842923++Antibacterial, antifungal, anticancer activities and structural bioinformatics analysis of six naturally occurring temporins++10.1016/j.peptides.2018.05.011++2018",0,Temporin-1Oc,Free,Amidation
DCTPep02325,BFTC-905,Bladder carcinoma ,Carcinoma,~40% Cell death=40 µg/ml,KRKCPKTPFDNTPGAWFAHLILGC,24,Lactobacillus casei; Lactobacillus paracasei,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Induce apoptosis,2701.2,2699.38,9.39,EMQSVY,KP,C124H190N34O30S2,4,"Ext. coefficient     5625##Abs 0.1% (=1 g/l)   2.082, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.036, assuming all Cys residues are reduced","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",41.77,57.08,-0.333,25557887++Antimicrobial peptide m2163 or m2386 identified from Lactobacillus casei ATCC 334 can trigger apoptosis in the human colorectal cancer cell line SW480++10.1007/s13277-014-3018-2++2015,0,m2163,Free,Free
DCTPep02363,A549,Lung adenocarcinoma,Carcinoma,LC50>100 µM,ILGAILPLVSGLLSNKL,17,Alytes obstetricans,Native peptide,Anticancer; Antibacterial; Antifungal,Cancer therapy related peptides,1721.16,1720.09,8.75,CDEFHMQRTWY,L,C81H145N19O21,1,Should not be visible by UV spectrophotometry.,"20 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",47.34,206.47,1.553,22392897++Analogues of the frog skin peptide alyteserin-2a with enhanced antimicrobial activities against Gram-negative bacteria++10.1002/psc.2397++2012,0,Alyteserin-2b,Free,Amidation
DCTPep02603,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,50% Cell death>128 µg/ml,WLRRIGKGVKIIGGAALDHL,20,Synthetic,Synthetic peptide,Anticancer,Cancer therapy related peptides,2173.64,2172.3,11.00,CEFMNPQSTY,G,C100H169N31O23,4,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.530,"2.8 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",41.69,141.50,0.335,21729875++The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents++10.1242/dmm.007310++2011,0,NRC-02,Free,Amidation
DCTPep02687,A431,Skin squamous cell carcinoma,Carcinoma,<10% Cytotoxicity=10 µM,VDKGSYLPRPTPPRPIYNRN,20,Pyrrhocoris apterus,Native peptide,Anticancer; Antibacterial,Cancer therapy related peptides,2340.67,2339.25,10.27,ACEFHMQW,P,C105H166N32O29,3,Ext. coefficient     2980##Abs 0.1% (=1 g/l)   1.273,"100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",30.65,53.50,-1.395,31209863++Identification and elucidation of proline-rich antimicrobial peptides with enhanced potency and delivery++10.1002/bit.27092++2019,0,Pyrrhocoricin,Free,Free
DCTPep00004,A549,Lung adenocarcinoma,Carcinoma,IC50=100 µM,KWKLFKKIKFLHSAKKF,17,Ceropin-Magainin hybrid peptides,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2177.75,2176.34,10.78,CDEGMNPQRTVY,K,C110H173N27O19,8,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.526,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-14.41,74.71,-0.582,"10675500++Effects of the hinge region of cecropin A(1-8)-magainin 2(1-12), a synthetic antimicrobial peptide, on liposomes, bacterial and tumor cells++10.1016/s0005-2736(99)00210-2++2000",0,CA-MA1,Free,Amidation
DCTPep00266,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,75% Cytotoxicity at 0.5 µg/ml,GIGKFLKKAKKFGKAFVKILKK,22,Helical peptide with a predominance of one or more amino acids tryptophane-rich,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide,2478.2,2476.61,10.90,CDEHMNPQRSTWY,K,C122H209N31O23,9,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-6.16,93.18,-0.159,"21403917++Antitumor activity of antimicrobial peptides against U937 histiocytic cell line++Not available++2011##8573171++A novel antimicrobial peptide from Bufo bufo gargarizans++10.1006/bbrc.1996.0071++1996##24587350++Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity++10.1371/journal.pone.0090397++2014",0,Pexiganan MSI-78,Free,Amidation
DCTPep00467,NCI-H838,Lung adenocarcinoma,Carcinoma,IC50=52.5μM,FLSLIPSLVGGSISAFK,17,Tityus serrulatus (Brazilian yellow scorpion),Native peptide,Anticance; Antimicrobial; Antibacterial,ACP##Tumor active peptide,1736.08,1734.99,8.75,CDEHMNQRTWY,S,C83H134N18O22,1,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",12.47,137.65,1.324,"23770440++Two peptides, TsAP-1 and TsAP-2, from the venom of the Brazilian yellow scorpion, Tityus serrulatus: evaluation of their antimicrobial and anticancer activities++10.1016/j.biochi.2013.06.003++2013",0,TsAP-1 (T. serrulatus antimicrobial peptide 1),Free,Amidation
DCTPep00944,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=13.7 µM,ILPWKWPWWPWRR,13,porcine cathelicidin peptide,Synthetic peptide,Anticancer,ACP##Tumor active peptide,1907.3,1906.03,12.01,ACDEFGHMNQSTVY,W,C100H131N25O14,3,Ext. coefficient    27500##Abs 0.1% (=1 g/l)  14.418,"20 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",76.28,60.00,-1.069,32126228++Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin++10.1016/j.bbamem.2020.183228++2020,0,Indolicidin-Arg,Free,Amidation
DCTPep01606,PC-3,Prostate carcinoma,Carcinoma,LD50=1000 µg/ml,FAKIIAKIAKIAKKIL,16,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1769.33,1768.21,10.60,CDEGHMNPQRSTVWY,IK,C87H157N21O17,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",0.19,171.25,1.050,Not available++Not available++Not available++Not available,0,FLAK50 Z8,Free,Amidation
DCTPep01612,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,LD50=380 µg/ml,FAKKLAKKLAKAAL,14,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1500.93,1499.99,10.60,CDEGHIMNPQRSTVWY,AK,C72H129N19O15,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-2.84,119.29,0.264,Not available++Not available++Not available++Not available,0,FLAK 58,Free,Amidation
DCTPep01613,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,LD50=260 µg/ml,FAKKLAKKLAKAL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1429.86,1428.95,10.60,CDEGHIMNPQRSTVWY,K,C69H124N18O14,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,120.77,0.146,Not available++Not available++Not available++Not available,0,FLAK 54,Free,Amidation
DCTPep01614,BMKC,Skin carcinoma,Carcinoma,LD50=160 µg/ml,FAKKLAKKLAKLAL,14,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1543.02,1542.04,10.60,CDEGHIMNPQRSTVWY,K,C75H135N19O15,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-8.91,140.00,0.407,Not available++Not available++Not available++Not available,0,FLAK57,Free,Amidation
DCTPep01615,SW480,Colon adenocarcinoma,Carcinoma,LD50=17 µg/ml,FAKKLAKKLAKLL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1471.94,1471,10.60,CDEGHIMNPQRSTVWY,K,C72H130N18O14,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,143.08,0.300,Not available++Not available++Not available++Not available,0,FLAK 56,Free,Amidation
DCTPep01616,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=190 µg/ml,FAKKLAKKLKKLAKKLAK,18,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2055.71,2054.42,10.90,CDEGHIMNPQRSTVWY,K,C99H183N27O19,9,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-14.14,108.89,-0.550,Not available++Not available++Not available++Not available,0,Shiva 10(1-18 AC),Free,Free
DCTPep01619,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,LD50=100 µg/ml,FAKKLAKKLKKLAKKLAKLAKKL,23,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2609.46,2607.81,11.00,CDEGHIMNPQRSTVWY,K,C126H234N34O24,11,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-16.27,123.48,-0.361,Not available++Not available++Not available++Not available,0,Anubis-2,Free,Amidation
DCTPep01623,SW480,Colon adenocarcinoma,Carcinoma,LD50=120 µg/ml,FAKKLAKKLKKLAKLALAK,19,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2111.78,2110.44,10.85,CDEGHIMNPQRSTVWY,K,C102H187N27O20,8,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.87,128.95,-0.021,Not available++Not available++Not available++Not available,0,FLAK 06R-AM,Free,Amidation
DCTPep01624,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=170 µg/ml,FAKKLAKKLKKLAKLALAL,19,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2096.76,2095.43,10.78,CDEGHIMNPQRSTVWY,K,C102H186N26O20,7,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.87,149.47,0.384,Not available++Not available++Not available++Not available,0,FLAK06 AM,Free,Amidation
DCTPep01626,BMKC,Skin carcinoma,Carcinoma,LD50=155 µg/ml,FAKKLAKKLL,10,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1159.52,1158.79,10.48,CDEGHIMNPQRSTVWY,K,C57H102N14O11,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.98,137.00,0.220,Not available++Not available++Not available++Not available,0,FLAK82,Free,Amidation
DCTPep01627,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=130 µg/ml,FAKKLAKLAKKALAL,15,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1614.09,1613.08,10.60,CDEGHIMNPQRSTVWY,AK,C78H140N20O16,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-1.99,137.33,0.500,Not available++Not available++Not available++Not available,0,FLAK44 AM,Free,Amidation
DCTPep01628,PC-3,Prostate carcinoma,Carcinoma,LD50=1000 µg/ml,FAKKLAKLAKKL,12,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1358.78,1357.92,10.60,CDEGHIMNPQRSTVWY,K,C66H119N17O13,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.06,122.50,0.008,Not available++Not available++Not available++Not available,0,FLAG26-D1,Free,Amidation
DCTPep01637,BMKC,Skin carcinoma,Carcinoma,LD50=150 µg/ml,FAKKLKKLAKLAKKL,15,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1728.28,1727.19,10.78,CDEGHIMNPQRSTVWY,K,C84H154N22O16,7,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-18.97,124.00,-0.260,Not available++Not available++Not available++Not available,0,FLAK71,Free,Amidation
DCTPep01638,PC-3,Prostate carcinoma,Carcinoma,LD50=1000 µg/ml,FAKKLLAKALKL,12,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1343.76,1342.91,10.48,CDEGHIMNPQRSTVWY,KL,C66H118N16O13,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.06,155.00,0.650,Not available++Not available++Not available++Not available,0,FLAG26-D3,Free,Amidation
DCTPep01640,PC-3,Prostate carcinoma,Carcinoma,LD50=1000 µg/ml,FAKLAKKALAKLL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1414.84,1413.94,10.48,CDEGHIMNPQRSTVWY,AKL,C69H123N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,150.77,0.738,Not available++Not available++Not available++Not available,0,FLAK91B,Free,Amidation
DCTPep01642,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FAKLF,5,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not available++Not available++Not available++Not available,0,FLAK91,Free,Amidation
DCTPep01644,PC-3,Prostate carcinoma,Carcinoma,LD50=1000 µg/ml,FAKLFAKLAKKFAL,14,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1596.03,1595,10.48,CDEGHIMNPQRSTVWY,AK,C81H130N18O15,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-2.84,112.14,0.814,Not available++Not available++Not available++Not available,0,FLAK50 Q9,Free,Amidation
DCTPep01649,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=150 µg/ml,FAKLLAKALKKL,12,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1343.76,1342.91,10.48,CDEGHIMNPQRSTVWY,KL,C66H118N16O13,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.06,155.00,0.650,Not available++Not available++Not available++Not available,0,FLAK 50P,Free,Amidation
DCTPep01651,BMKC,Skin carcinoma,Carcinoma,LD50=160 µg/ml,FAKLLAKALKLKL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-23.42,173.08,0.892,Not available++Not available++Not available++Not available,0,FLAK 50N,Free,Amidation
DCTPep01657,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,LD50=210 µg/ml,FAKLLAKLAKAKL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1414.84,1413.94,10.48,CDEGHIMNPQRSTVWY,AKL,C69H123N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,150.77,0.738,Not available++Not available++Not available++Not available,0,FLAK 50H,Free,Amidation
DCTPep01659,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=320 µg/ml,FAKLLAKLAKKAA,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1372.76,1371.9,10.48,CDEGHIMNPQRSTVWY,A,C66H117N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,128.46,0.585,Not available++Not available++Not available++Not available,0,FLAK50J,Free,Amidation
DCTPep01660,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,LD50=190 µg/ml,FAKLLAKLAKKAL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1414.84,1413.94,10.48,CDEGHIMNPQRSTVWY,AKL,C69H123N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,150.77,0.738,Not available++Not available++Not available++Not available,0,FLAK50C,Free,Amidation
DCTPep01662,PC-3,Prostate carcinoma,Carcinoma,LD50=1000 µg/ml,FAKLLAKLAKKFAL,14,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1562.02,1561.01,10.48,CDEGHIMNPQRSTVWY,AKL,C78H132N18O15,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-2.84,140.00,0.886,Not available++Not available++Not available++Not available,0,FLAK50 Q8,Free,Amidation
DCTPep01663,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FAKLLAKLAKKGL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1400.81,1399.93,10.48,CDEHIMNPQRSTVWY,KL,C68H121N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-10.36,143.08,0.569,Not available++Not available++Not available++Not available,0,FLAK50T7,Free,Amidation
DCTPep01664,SW480,Colon adenocarcinoma,Carcinoma,LD50=125 µg/ml,FAKLLAKLAKKIL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1456.92,1455.99,10.48,CDEGHMNPQRSTVWY,KL,C72H129N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",4.45,173.08,0.946,Not available++Not available++Not available++Not available,0,FLAK50 T3,Free,Amidation
DCTPep01665,SW480,Colon adenocarcinoma,Carcinoma,LD50=100 µg/ml,FAKLLAKLAKKL,12,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1343.76,1342.91,10.48,CDEGHIMNPQRSTVWY,KL,C66H118N16O13,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.06,155.00,0.650,Not available++Not available++Not available++Not available,0,FLAK50F,Free,Amidation
DCTPep01667,PC-3,Prostate carcinoma,Carcinoma,LD50=1000 µg/ml,FAKLLAKLAKKSL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1430.84,1429.94,10.48,CDEGHIMNPQRTVWY,KL,C69H123N17O15,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,143.08,0.538,Not available++Not available++Not available++Not available,0,FLAK50 T5,Free,Amidation
DCTPep01669,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=130 µg/ml,FAKLLAKLAKLKL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-23.42,173.08,0.892,Not available++Not available++Not available++Not available,0,FLAK 50G,Free,Amidation
DCTPep01671,BMKC,Skin carcinoma,Carcinoma,LD50=445 µg/ml,FAKLLFKALKKAL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1490.94,1489.97,10.48,CDEGHIMNPQRSTVWY,KL,C75H127N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-15.39,143.08,0.815,Not available++Not available++Not available++Not available,0,FLAK50 Q2,Free,Amidation
DCTPep01672,BMKC,Skin carcinoma,Carcinoma,LD50=205 µg/ml,FAKLLKLAAKKLL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-16.89,173.08,0.892,Not available++Not available++Not available++Not available,0,FLAK 50E,Free,Amidation
DCTPep01674,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,LD50=400 µg/ml,FAKLWAKLAKKL,12,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1416.82,1415.9,10.48,CDEGHIMNPQRSTVY,K,C71H117N17O13,4,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.882,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-4.85,122.50,0.258,Not available++Not available++Not available++Not available,0,FLAK50 Z5,Free,Amidation
DCTPep01682,PC-3,Prostate carcinoma,Carcinoma,LD50=1000 µg/ml,FALALKALKK,10,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1102.43,1101.73,10.30,CDEGHIMNPQRSTVWY,AKL,C54H95N13O11,3,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.98,147.00,0.790,Not available++Not available++Not available++Not available,0,FLAK96F,Free,Amidation
DCTPep01684,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=150 µg/ml,FALALKALKKAL,12,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1286.67,1285.85,10.30,CDEGHIMNPQRSTVWY,AL,C63H111N15O13,3,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-4.98,163.33,1.125,Not available++Not available++Not available++Not available,0,FLAK96,Free,Amidation
DCTPep01686,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=44 µg/ml,FALALKALKKALKKLKKALKKAL,23,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2537.35,2535.74,10.90,CDEGHIMNPQRSTVWY,K,C123H226N32O24,9,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.58,144.78,0.222,Not available++Not available++Not available++Not available,0,Hecate Ac,Free,Free
DCTPep01694,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=230 µg/ml,FALALKLAKKAL,12,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1286.67,1285.85,10.30,CDEGHIMNPQRSTVWY,AL,C63H111N15O13,3,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-4.98,163.33,1.125,Not available++Not available++Not available++Not available,0,FLAK96B,Free,Amidation
DCTPep01700,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=305 µg/ml,FALLKALKKAL,11,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1215.59,1214.81,10.30,CDEGHIMNPQRSTVWY,L,C60H106N14O12,3,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-6.35,169.09,1.064,Not available++Not available++Not available++Not available,0,FLAK96D,Free,Amidation
DCTPep01701,PC-3,Prostate carcinoma,Carcinoma,LD50=120 µg/ml,FALLKALLKKAL,12,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1328.75,1327.9,10.30,CDEGHIMNPQRSTVWY,L,C66H117N15O13,3,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-4.98,187.50,1.292,Not available++Not available++Not available++Not available,0,Flak 96I,Free,Amidation
DCTPep01703,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=240 µg/ml,FAVGLRAIKRALKKLRRGVRKVAKDL,26,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2963.7,2961.9,12.19,CEHMNPQSTWY,KR,C134H244N46O29,9,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",39.41,123.85,-0.154,Not available++Not available++Not available++Not available,0,FAGVL,Free,Amidation
DCTPep01705,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=360 µg/ml,FKLAFKLAKKAFL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1524.96,1523.96,10.48,CDEGHIMNPQRSTVWY,K,C78H125N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-26.95,113.08,0.738,Not available++Not available++Not available++Not available,0,FLAK50 Q10,Free,Amidation
DCTPep01707,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,LD50=1000 µg/ml,FKVKFKVKVK,10,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1250.64,1249.83,10.60,ACDEGHILMNPQRSTWY,K,C63H107N15O11,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-55.17,87.00,-0.130,Not available++Not available++Not available++Not available,0,KSL-7,Free,Amidation
DCTPep01718,PC-3,Prostate carcinoma,Carcinoma,LD50=1000 µg/ml,KKVVFKVKFK,10,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1250.64,1249.83,10.60,ACDEGHILMNPQRSTWY,K,C63H107N15O11,5,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-40.92,87.00,-0.130,Not available++Not available++Not available++Not available,0,KSL-1,Free,Amidation
DCTPep01721,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=160 µg/ml,KLALKLALKALKAAKLA,17,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1764.31,1763.21,10.60,CDEFGHIMNPQRSTVWY,AL,C84H158N22O18,5,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-20.55,172.94,0.829,Not available++Not available++Not available++Not available,0,FLAK99,Free,Amidation
DCTPep01725,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=115 µg/ml,KWKLAKKALALL,12,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1382.8,1381.92,10.48,CDEFGHIMNPQRSTVY,KL,C68H119N17O13,4,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.977,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",2.09,155.00,0.342,Not available++Not available++Not available++Not available,0,FLAK93B,Free,Amidation
DCTPep01730,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=110 µg/ml,KYKKALKKLAKLL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1545.03,1544.05,10.40,CDEFGHIMNPQRSTVW,K,C75H137N19O15,6,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.964,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-10.36,135.38,-0.454,Not available++Not available++Not available++Not available,0,FLAK98,Free,Amidation
DCTPep01734,BMKC,Skin carcinoma,Carcinoma,LD50=120 µg/ml,MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG,38,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,4089,4086.41,10.73,CDHQSTY,K,C188H320N54O45S1,7,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.345,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",31.93,105.26,-0.008,Not available++Not available++Not available++Not available,0,SB-37 AC,Free,Free
DCTPep01744,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=315 µg/ml,VAKLLAKLAKKVL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1394.85,1393.97,10.48,CDEFGHIMNPQRSTWY,KL,C67H127N17O14,4,Should not be visible by UV spectrophotometry.,"100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-10.36,187.69,1.031,Not available++Not available++Not available++Not available,0,FLAK50T8,Free,Amidation
DCTPep01745,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=160 µg/ml,VALALKALKKALKKLKKALKKAL,23,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2489.3,2487.74,10.90,CDEFGHIMNPQRSTWY,K,C119H226N32O24,9,Should not be visible by UV spectrophotometry.,"100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-12.58,157.39,0.283,Not available++Not available++Not available++Not available,0,Hecate AC V,Free,Free
DCTPep01750,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=260 µg/ml,WALAL,5,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not available++Not available++Not available++Not available,0,FLAK-120F,Free,Amidation
DCTPep00020,ME-180,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,100% Cytotoxicity=200 µg/ml,KNLRRIIRKIIHIIKKYG,18,Synthetic,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,2262.86,2261.47,11.75,ACDEFMPQSTVW,I,C105H188N34O21,8,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.658,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",69.08,151.67,-0.372,11932493++Impact of single-residue mutations on the structure and function of ovispirin/novispirin antimicrobial peptides++10.1093/protein/15.3.225++2002,0,ovispirin-1,Free,Free
DCTPep00026,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,IC50=3.5 µM,KWKFKKIPKFLHLAKKF,17,Ceropin A,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2187.79,2186.36,10.78,CDEGMNQRSTVY,K,C112H175N27O18,8,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.514,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-6.12,74.71,-0.629,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",0,P18,Free,Amidation
DCTPep00027,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,IC50=3 µM,KWKLFKKILKFLHLAKKF,18,Ceropin A,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2316.99,2315.48,10.78,CDEGMNPQRSTVY,K,C119H190N28O19,8,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.374,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-2.36,113.89,-0.083,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",0,[L9]-P18,Free,Amidation
DCTPep00028,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,IC50=3 µM,KWKLFKKISKFLHLAKKF,18,Ceropin A,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2290.91,2289.42,10.78,CDEGMNPQRTVY,K,C116H184N28O20,8,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.401,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-8.34,92.22,-0.339,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",0,[S9]-P18,Free,Amidation
DCTPep00030,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=11 µM,FKLFKKIPKFLHLAKKF,17,Ceropin A,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2133.74,2132.34,10.70,CDEGMNQRSTVWY,K,C110H173N25O18,7,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-19.95,97.65,0.041,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",0,N-2,Free,Amidation
DCTPep00033,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=100.0< µM,WKKIPKFLHLAKKF,14,Ceropin A,Synthetic peptide,Anticancer; Antibacterial,Membrane-targeted,1784.27,1783.1,10.60,CDEGMNQRSTVY,K,C91H142N22O15,6,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.082,"2.8 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",1.16,90.71,-0.407,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",0,N-5,Free,Amidation
DCTPep00042,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=21 µM,KWKLFKKIPKFLHLA,15,Ceropin A,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,1897.43,1896.19,10.60,CDEGMNQRSTVY,K,C97H153N23O16,6,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.899,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-13.93,110.67,-0.127,"12005420++Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs++10.1034/j.1399-3011.2001.00934.x++2001",0,C-6,Free,Amidation
DCTPep00047,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,IC50=1.8 µM,KSCCPSTTARNIYNTCRLTGASRSVCASLSGCKIISGSTCDSGWNH,46,Phoradendron liga,Native peptide,Anticancer,ACP##Tumor active peptide##Membrane-targeted,4798.41,4795.18,8.94,EFMQ,S,C194H319N63O67S6,5,"Ext. coefficient     7365##Abs 0.1% (=1 g/l)   1.535, assuming all pairs of Cys residues form cystines##Ext. coefficient     6990##Abs 0.1% (=1 g/l)   1.457, assuming all Cys residues are reduced","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",57.57,55.22,-0.193,"12049612++Ligatoxin B, a new cytotoxic protein with a novel helix-turn-helix DNA-binding domain from the mistletoe Phoradendron liga++10.1042/BJ20020221++2002",0,Ligatoxin-B,Free,Free
DCTPep00056,MT-1,Human mammary carcinoma,Carcinoma,IC50=16 µM,PAWFKARRWAWRMLKKAA,18,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,2273.78,2272.27,12.31,CDEGHINQSTVY,A,C109H165N33O19S1,6,Ext. coefficient    16500##Abs 0.1% (=1 g/l)   7.257,">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",62.37,49.44,-0.667,12366526++Enhanced antitumor activity and selectivity of lactoferrin-derived peptides++10.1034/j.1399-3011.2002.21008.x++2002,0,L4,Free,Free
DCTPep00059,MT-1,Human mammary carcinoma,Carcinoma,IC50=11 µM,PAWRKAFRAAWRMLKKAA,18,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,2158.64,2157.23,12.31,CDEGHINQSTVY,A,C101H160N32O19S1,6,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   5.096,">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",15.43,55.00,-0.517,12366526++Enhanced antitumor activity and selectivity of lactoferrin-derived peptides++10.1034/j.1399-3011.2002.21008.x++2002,0,L7,Free,Free
DCTPep00065,MT-1,Human mammary carcinoma,Carcinoma,IC50=12 µM,PAWRKAFRKAWRMLKKAA,18,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,2215.74,2214.28,12.31,CDEGHINQSTVY,A,C104H167N33O19S1,7,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   4.964,">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",15.43,49.44,-0.833,12366526++Enhanced antitumor activity and selectivity of lactoferrin-derived peptides++10.1034/j.1399-3011.2002.21008.x++2002,0,L13,Free,Free
DCTPep00071,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CC50=16.1±0.4 μM,GLPVCGETCVGGTCNTPGCSCSWPVCTRN,29,Viola arvensis (European field pansy) (Field violet),Native peptide,Anticancer,ACP##Tumor active peptide##Membrane-targeted,2902.32,2900.18,5.96,ADFHIKMQY,C,C116H185N35O40S6,0,"Ext. coefficient     5875##Abs 0.1% (=1 g/l)   2.024, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.895, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",46.59,43.45,0.148,12477048++Cyclotides: a novel type of cytotoxic agents++10.1097/00008390-200204000-00013++2002##20580652++Isolation and characterization of cytotoxic cyclotides from Viola tricolor++10.1016/j.peptides.2010.05.004++2010##10600388++Plant cyclotides: A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif++10.1006/jmbi.1999.3383++1999##25099014++Anticancer and toxic properties of cyclotides are dependent on phosphatidylethanolamine phospholipid targeting++10.1002/cbic.201402144++2014,0,"Varv A, Kalata B1 [T20S]",Free,Free
DCTPep00077,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,60% Cytotoxicity at 0.5 µg/ml,GLFDVIKKVASVIGGL,16,Amphibian skin secretions,Native peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,1615.98,1614.97,8.59,CEHMNPQRTWY,GV,C76H130N18O20,1,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",14.19,158.12,1.281,"12631273++nNOS inhibition, antimicrobial and anticancer activity of the amphibian skin peptide, citropin 1.1 and synthetic modifications++10.1046/j.1432-1033.2003.03462.x++2003##21403917++Antitumor activity of antimicrobial peptides against U937 histiocytic cell line++Not available++2011##8573171++A novel antimicrobial peptide from Bufo bufo gargarizans++10.1006/bbrc.1996.0071++1996",0,Citropin 1.1,Free,Amidation
DCTPep00087,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,IC50=10 μM,GLFAVIKKVAAVIKKL,16,Amphibian skin secretions,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane-targeted,1698.21,1697.13,10.48,CDEHMNPQRSTWY,K,C83H148N20O17,4,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-11.85,170.62,1.337,"12631273++nNOS inhibition, antimicrobial and anticancer activity of the amphibian skin peptide, citropin 1.1 and synthetic modifications++10.1046/j.1432-1033.2003.03462.x++2003",0,Citropin 17,Free,Amidation
DCTPep00099,A549,Lung adenocarcinoma,Carcinoma,IC50>100 µg/ml,LLAGLAANFLPTIICKISYKC,21,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,Induce apoptosis,2252.8,2251.25,8.86,DEHMQRVW,L,C105H174N24O26S2,2,"Ext. coefficient     1615##Abs 0.1% (=1 g/l)   0.717, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.661, assuming all Cys residues are reduced","5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",7.5,144.29,1.229,14499271++In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines++10.1016/s0196-9781(03)00194-3++2003,0,PTP1,Free,Amidation
DCTPep00117,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,IC50=45 µM,CFKFKFKFGSGFKFKFKFC,19,Synthetic,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2371.93,2370.22,10.05,ADEHILMNPQRTVWY,F,C121H167N25O21S2,6,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.053, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-37.99,0.00,0.126,15328096++De novo design of potent antimicrobial peptides++10.1128/AAC.48.9.3349-3357.2004++2004,0,V6,Acetylization,Amidation
DCTPep00127,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,19% inhibition at 7 mg/kg/d,MRGIRGADFQAFQQARAVGLAGTFR,25,Human endostatin peptides,Native peptide,Anticancer; Antiangiogenesis,Cancer targeted peptides,2725.13,2723.42,12.00,CEHKNPSWY,A,C119H190N40O32S1,3,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-7.56,62.80,-0.100,15867360++A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity++10.1158/0008-5472.CAN-04-1833++2005,0,hP2,Free,Free
DCTPep00133,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,No inhibition at 7 mg/kg/d,LGQSAASAHHAYIVLAIENSFMTASKKK,28,Human endostatin peptides,Native peptide,Anticancer; Antiangiogenesis,Cancer targeted peptides,2974.43,2972.55,9.53,CDPRW,A,C132H213N37O39S1,4,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.501,"5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",33.94,87.50,0.075,15867360++A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity++10.1158/0008-5472.CAN-04-1833++2005,0,hP8,Free,Free
DCTPep00137,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,IC50=37 µM,MWKWFHNVLSSWQLLADKRPARDYNRK,27,S. pneumoniae,Synthetic peptide,Anticancer,ACP##Tumor active peptide,3446.98,3444.78,10.43,CEGIT,KLRW,C159H237N47O38S1,5,Ext. coefficient    17990##Abs 0.1% (=1 g/l)   5.219,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",45.59,61.48,-1.081,16004618++Functional and structural characteristics of anticancer peptide Pep27 analogues++10.1186/1475-2867-5-21++2005,0,Pep27anal1,Free,Free
DCTPep00145,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,20.8% cytotoxic at 1 µg/ml,YSL,3,Synthetic,Synthetic peptide,Anticancer,ACP##Tumor active peptide,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"16091933++Tripeptide tyroserleutide enhances the antitumor effects of macrophages and stimulates macrophage secretion of IL-1beta, TNF-alpha, and NO in vitro++10.1007/s00262-005-0024-10++2006",0,Tyroserleutide,Free,Free
DCTPep00167,HCT 116,Colon carcinoma,Carcinoma,IC50=113.31 µg/ml,FLGALFKVASKVLPSVKCAITKKC,24,Rana rugosa,Synthetic peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,2552.22,2550.48,9.90,DEHMNQRWY,K,C119H203N29O28S2,5,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.049, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",7.56,113.75,0.863,16884301++Structural determinants for the membrane interaction of novel bioactive undecapeptides derived from gaegurin 5++10.1021/jm050996u++2006##14739294++Systematic peptide engineering and structural characterization to search for the shortest antimicrobial peptide analogue of gaegurin 5++10.1074/jbc.M309822200++2004,0,Gaegurin-5,Free,Free
DCTPep00205,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,LD50=12 μM,FLPAIVGAAAKFLPKIFCAISKKC,24,"North America, leopard frog, Lithobates blairi",Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane lysis,2537.21,2535.45,9.70,DEHMNQRTWY,A,C122H198N28O26S2,4,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.049, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",19.51,114.17,1.154,"19254736++Peptides with potent cytolytic activity from the skin secretions of the North American leopard frogs, Lithobates blairi and Lithobates yavapaiensis++10.1016/j.toxicon.2009.02.018++2009",0,Brevinin-1BLa,Free,Free
DCTPep00214,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,IC50>200 µM,SAVGRHGRRFGLRKHRKH,18,"skin of the Chinese brown frog, Rana chensinensis",Native peptide,Anticancer,Cancer therapy related peptides,2155.51,2154.24,12.60,CDEIMNPQTWY,R,C92H155N41O20,10,Should not be visible by UV spectrophotometry.,"1.9 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",52.19,43.33,-1.628,"19341344++Molecular cloning of cDNAs encoding antimicrobial peptide precursors from the skin of the Chinese brown frog, Rana chensinensis++10.2108/zsj.26.220++2009",0,Chensinin-1,Free,Amidation
DCTPep00233,B16-F10,Mouse melanoma,Carcinoma,40% inhibition at 5µg/ml,ACDCRGDCFCGGGGIVRRADRAAVP,25,Endostatin derived Synthetic,Synthetic peptide,Anticancer,ACP##Tumor active peptide##Cancer targeted peptides,2525.88,2524.13,7.93,EHKLMNQSTWY,G,C100H165N37O32S4,1,"Ext. coefficient      250##Abs 0.1% (=1 g/l)   0.099, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",63.7,54.80,0.032,20515045++Effect of RGD-4C Position is More Important Than Disulfide Bonds on Antiangiogenic Activity of RGD-4C Modified Endostatin Derived Synthetic Polypeptide++10.1021/bc900292y++2010,0,AP,Free,Free
DCTPep00236,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,IC50=26 μM,GIACGESCVFLGCFIPGCSCKSKVCYFN,28,Micronesian Plant Psychotria leptothyrsa,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,2936.5,2934.27,7.77,DHMQRTW,C,C128H195N31O36S6,1,"Ext. coefficient     1865##Abs 0.1% (=1 g/l)   0.635, assuming all pairs of Cys residues form cystines##Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.507, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",43.02,66.07,0.882,"20575512++Isolation, characterization, and bioactivity of cyclotides from the Micronesian plant Psychotria leptothyrsa++10.1021/np9007365++2010 ",0,Psyle A,Free,Free
DCTPep00238,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,IC50=3.5 μM,KLCGETCFKFKCYTPGCSCSYPFCK,25,Micronesian Plant Psychotria leptothyrsa,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,2844.4,2842.21,8.64,ADHIMNQRVW,C,C126H187N29O34S6,3,"Ext. coefficient     3355##Abs 0.1% (=1 g/l)   1.180, assuming all pairs of Cys residues form cystines##Ext. coefficient     2980##Abs 0.1% (=1 g/l)   1.048, assuming all Cys residues are reduced","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",13.45,15.60,-0.060,"20575512++Isolation, characterization, and bioactivity of cyclotides from the Micronesian plant Psychotria leptothyrsa++10.1021/np9007365++2010 ",0,Psyle C,Free,Free
DCTPep00255,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=2 μmol/L,KWKSFLKTFKSLKKTVLHTLLKAISS,26,PeptideV13K,Synthetic peptide,Anticancer,ACP##Tumor active peptide##Membrane-targeted,3033.74,3031.83,10.78,CDEGMNPQRY,K,C145H242N36O34,8,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.813,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",3.29,105.00,-0.062,21252288++Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework++10.1158/1535-7163.MCT-10-0811++2011##15677462++Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index++10.1074/jbc.M413406200++2005,0,A12L/A20L,Acetylation,Amidation
DCTPep00262,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,5% Cytotoxicity at 0.5 µg/ml,TRSSRAGLQFPVGRVHRLLRK,21,Bufo Bufo Gargarizans,Native peptide,Anticancer; Antimicrobial,Antiangiogenic,2434.88,2433.43,12.60,CDEIMNWY,R,C106H184N40O26,7,Should not be visible by UV spectrophotometry.,"7.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",84.2,88.10,-0.638,21403917++Antitumor activity of antimicrobial peptides against U937 histiocytic cell line++Not available++2011##8573171++A novel antimicrobial peptide from Bufo bufo gargarizans++10.1006/bbrc.1996.0071++1996,0,Buforin II,Free,Amidation
DCTPep00272, --, --, --,IC50 for MDM2=0.57 µM,PRAWEYWLRLME,12,E3 ubiquitin-protein ligase,Synthetic peptide,Anticancer; Antitumor,ACP##Tumor active peptide##Cancer targeted peptides##Affect cell cycle,1649.93,1648.82,6.57,CDFGHIKNQSTV,ELRW,C78H112N20O18S1,0,Ext. coefficient    12490##Abs 0.1% (=1 g/l)   7.570,">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",20.57,73.33,-0.783,21423613++mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction++10.1371/journal.pone.0017898++2011,0,MIP(F3A),Free,Free
DCTPep00276, --, --, --,IC50 for MDM2=1.14 µM,PRFWEYWLRAME,12,E3 ubiquitin-protein ligase,Synthetic peptide,Anticancer; Antitumor,ACP##Tumor active peptide##Cancer targeted peptides##Affect cell cycle,1683.95,1682.8,6.57,CDGHIKNQSTV,ERW,C81H110N20O18S1,0,Ext. coefficient    12490##Abs 0.1% (=1 g/l)   7.417,">20 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##? (Escherichia coli, in vivo).",20.57,40.83,-0.867,21423613++mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction++10.1371/journal.pone.0017898++2011,0,MIP(L10A),Free,Free
DCTPep00325,HT-29,Colon adenocarcinoma,Carcinoma,EC50=13 µM,AAWKWAWAKKWAKAKKWAKAA,21,Synthetic,Synthetic peptide,Anticancer,ACP##Tumor active peptide,2486.01,2484.41,10.78,CDEFGHILMNPQRSTVY,A,C124H181N33O22,7,Ext. coefficient    27500##Abs 0.1% (=1 g/l)  11.062,"4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-19.1,42.86,-0.743,22057278++Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity++10.1074/jbc.M111.279281++2012,0,Z9,Free,Free
DCTPep00328,Meth A,Mouse fibrosarcoma,Sarcoma,EC50=15 µM,KAAKKAWKAAKKAWKAAKKAA,21,Synthetic,Synthetic peptide,Anticancer,ACP##Tumor active peptide,2254.8,2253.39,10.90,CDEFGHILMNPQRSTVY,A,C106H180N32O22,9,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   4.878,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",9.52,47.62,-0.900,22057278++Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity++10.1074/jbc.M111.279281++2012,0,Z7,Free,Free
DCTPep00340,SW480,Colon adenocarcinoma,Carcinoma,IC50=16 µM,AFGMALKLLKKVL,13,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,1431.89,1430.9,10.30,CDEHINPQRSTWY,L,C69H122N16O14S1,3,Should not be visible by UV spectrophotometry.,"4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-7.4,157.69,1.200,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,0,MAC1/2,Free,Amidation
DCTPep00355,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50> 100 µM,GKWKKILGHLIR,12,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,Membrane-targeted,1448.82,1447.91,11.26,ACDEFMNPQSTVY,K,C69H117N21O13,5,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.796,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",11.07,130.00,-0.375,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,0,HAL-1/19,Free,Amidation
DCTPep00383,SW480,Colon adenocarcinoma,Carcinoma,IC50=15 µM,VNWKKLLGKLLKVVK,15,Synthetic,Synthetic peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide##Membrane-targeted,1766.29,1765.17,10.60,ACDEFHIMPQRSTY,K,C86H152N22O17,5,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.114,"100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-27.8,162.00,0.233,22100226++Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells++10.1016/j.peptides.2011.11.002++2012,0,LL-III/23,Free,Amidation
DCTPep00393,A549,Lung adenocarcinoma,Carcinoma,IC50>100µM,KVKVKVKVPPTKVKVKVK,18,Synthetic,Synthetic peptide,Anticancer,Membrane-targeted,2032.67,2031.4,10.85,ACDEFGHILMNQRSWY,K,C97H182N26O20,8,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-11.77,112.78,-0.317,22413859++Anticancer ?-hairpin peptides: membrane-induced folding triggers activity++10.1021/ja210569f++2012,0,SVS-3,Free,Free
DCTPep00395,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=9.8 μM,GASCGETCFTGICFTAGCSCNPWPTCTRN,29,Chassalia chartacea,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Membrane-targeted,2988.36,2986.16,5.96,DHKLMQVY,C,C122H183N35O41S6,0,"Ext. coefficient     5875##Abs 0.1% (=1 g/l)   1.966, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.840, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",34.27,20.34,0.100,22467870++Novel cyclotides and uncyclotides with highly shortened precursors from Chassalia chartacea and effects of methionine oxidation on bioactivities++10.1074/jbc.M111.338970++2012,0,Chassatide C4,Free,Free
DCTPep00444,J774A.1,Mouse reticulum cell sarcoma,Sarcoma,IC50=12 µM,RRRRRNWMWC,10,Nullomer derived anticancer peptides (NulloPs):,Native peptide,Anticancer,ACP##Tumor active peptide,1519.81,1518.77,12.18,ADEFGHIKLPQSTVY,R,C64H102N28O12S2,5,"Ext. coefficient    11000##Abs 0.1% (=1 g/l)   7.238, assuming all pairs of Cys residues form cystines##Ext. coefficient    11000##Abs 0.1% (=1 g/l)   7.238, assuming all Cys residues are reduced","1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",263.77,0.00,-2.340,23000474++Nullomer derived anticancer peptides (NulloPs): differential lethal effects on normal and cancer cells in vitro++10.1016/j.peptides.2012.09.015++2012,0,9R,Free,Amidation
DCTPep00448,HT-29,Colon adenocarcinoma,Carcinoma,IC50=132±12µM ,RWRWRW,6,Synthetic,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1045.22,1044.55,12.30,ACDEFGHIKLMNPQSTVY,RW,C51H68N18O7,3,Ext. coefficient    16500##Abs 0.1% (=1 g/l)  15.786,"1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",294.73,0.00,-2.700,23209509++Modulating the activity of short arginine-tryptophan containing antibacterial peptides with N-terminal metallocenoyl groups++10.3762/bjoc.8.200++2012##17145799++Length effects in antimicrobial peptides of the (RW)n series++10.1128/AAC.00828-06++2007,0,(RW)3,Free,Amidation
DCTPep00463,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50=10.52µM,FVKLKKILNIINSIFKK,17,Synthetic construct,Synthetic peptide,Anticancer,ACP##Tumor active peptide,2046.61,2045.31,10.60,ACDEGHMPQRTWY,K,C100H172N24O21,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",21.07,154.71,0.476,"23609760++Design of potent, non-toxic anticancer peptides based on the structure of the antimicrobial peptide, temporin-1CEa++10.1007/s12272-013-0112-8++2013",0,Temporin-1CEa LK2(6)A(L),Free,Amidation
DCTPep00467,NCI-H838,Lung adenocarcinoma,Carcinoma,IC50=52.5μM,FLSLIPSLVGGSISAFK,17,Tityus serrulatus (Brazilian yellow scorpion),Native peptide,Anticance; Antimicrobial; Antibacterial,ACP##Tumor active peptide,1736.08,1734.99,8.75,CDEHMNQRTWY,S,C83H134N18O22,1,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",12.47,137.65,1.324,"23770440++Two peptides, TsAP-1 and TsAP-2, from the venom of the Brazilian yellow scorpion, Tityus serrulatus: evaluation of their antimicrobial and anticancer activities++10.1016/j.biochi.2013.06.003++2013",0,TsAP-1 (T. serrulatus antimicrobial peptide 1),Free,Amidation
DCTPep00474,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,IC50>50 µM,RRWRIVVIRVRR,12,Synthetic,Synthetic peptide,Anticancer; Antibacterial; Antifungal,Cancer therapy related peptides,1665.07,1664.07,12.70,ACDEFGHKLMNPQSTY,R,C74H133N31O13,6,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   3.303,"1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",145.29,137.50,-0.525,24038773++The antimicrobial activity of Sub3 is dependent on membrane binding and cell-penetrating ability++10.1002/cbic.201300274++2013,0,Bac2a [L2R][A3W][A11R],Free,Amidation
DCTPep00478,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,100% Cytotoxicity at 5 µM Approx,GIIKKIIKKI,10,Alpha-helical proteins,Synthetic peptide,Anticancer,ACP##Tumor active peptide,1153.56,1152.83,10.48,ACDEFHLMNPQRSTVWY,I,C56H108N14O11,4,Should not be visible by UV spectrophotometry.,"30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-33.45,195.00,0.650,24246647++Molecular mechanisms of anticancer action and cell selectivity of short α-helical peptides++10.1016/j.biomaterials.2013.10.082++2014,0,Short α-helical peptides,Free,Amidation
DCTPep00503,HepG2,Hepatoblastoma,Blastoma,50% Cell death=52.51±3.6 µM,SMWSGMWRRKLKKLRNALKKKLKGE,25,Lachesana tarabaevi,Native peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,3073.8,3071.78,11.77,CDFHIPQTVY,K,C138H238N44O31S2,9,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   3.579,"1.9 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",18.36,66.40,-1.248,"24885331++Identification of natural antimicrobial agents to treat dengue infection: In vitro analysis of latarcin peptide activity against dengue virus++10.1186/1471-2180-14-140++2014##16735513++Latarcins, antimicrobial and cytolytic peptides from the venom of the spider Lachesana tarabaevi (Zodariidae) that exemplify biomolecular diversity++10.1074/jbc.M602168200++2006##34576320++Membrane Interactions of Latarcins: Antimicrobial Peptides from Spider Venom++10.3390/ijms221810156++2021",0,Latarcin-1,Free,Free
DCTPep00506,HCT 116,Colon carcinoma,Carcinoma,Cell viability >40% at 12.5μM approx,KILRGVAKKIMRTFLRRISKKILTGKK,27,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide##Membrane lysis,3184.07,3182.05,12.49,CDEHNPQWY,K,C145H268N46O31S1,11,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",42.29,115.56,-0.304,24962950++Host defense peptides for treatment of colorectal carcinoma - a comparative in vitro and in vivo analysis++10.18632/oncotarget.2039++2014,0,C7A-D21K,Free,Amidation
DCTPep00615,Eca 109,Esophageal squamous cell carcinoma; Squamous cell carcinoma of the esophagus,Carcinoma,30% Killing=20µM,RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK,37,Bombyx mori,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide,4079.95,4077.39,10.71,CHQTY,K,C185H317N55O46S1,7,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.348,"1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",61.88,100.27,-0.243,"27664674++A potential food biopreservative, CecXJ-37N, non-covalently intercalates into the nucleotides of bacterial genomic DNA beyond membrane attack++10.1016/j.foodchem.2016.09.033++2017",0,CecXJ-37N,Free,Amidation
DCTPep00741,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,IC50=8.7µM,GGTIFDCGESCFLGTCYTKGCSCGEWKLCYGTN,33,Viola odorata,Native peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,3504.96,3502.41,4.68,AHMPQRV,G,C149H219N37O49S6,-1,"Ext. coefficient     8855##Abs 0.1% (=1 g/l)   2.526, assuming all pairs of Cys residues form cystines##Ext. coefficient     8480##Abs 0.1% (=1 g/l)   2.419, assuming all Cys residues are reduced","30 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",11.08,35.45,0.006,28669767++Bactericidal activity of cyclotides where phosphatidylethanolamine-lipid selectivity determines antimicrobial spectra++10.1016/j.bbamem.2017.06.018++2017,0,Tricyclon-A,Free,Free
DCTPep00792,MDA-MB-231,Breast adenocarcinoma,Carcinoma,IC50>102 μM,FKARRWQWRMKKLGA,15,Bovine Lactoferricin,Native peptide,Anticancer; Antitumor; Antimicrobial,Cancer therapy related peptides,1962.4,1961.1,12.31,CDEHINPSTVY,KR,C91H144N30O17S1,6,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   5.605,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",64.37,39.33,-1.253,28961215++Antibacterial Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Cytotoxic Effect against MDA-MB-468 and MDA-MB-231 Breast Cancer Cell Lines++10.3390/molecules22101641++2017,0,LfcinB (17-31),Free,Free
DCTPep00828,NCI-H157,Lung squamous cell carcinoma,Carcinoma,IC50=15.67 μM,ALWKDILKNAGKAALNEINQIVQ,23,skin secretion of Phyllomedusa sauvagii,Native peptide,Anticancer; Antitumor; Antimicrobial,ACP##Tumor active peptide,2550.98,2549.43,8.54,CFHMPRSTY,A,C115H192N32O33,1,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.156,"4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",22.26,131.74,-0.052,"30087268++Biological Activities of Cationicity-Enhanced and Hydrophobicity-Optimized Analogues of an Antimicrobial Peptide, Dermaseptin-PS3, from the Skin Secretion of Phyllomedusa sauvagii++10.3390/toxins10080320++2018",0,DPS3,Free,Free
DCTPep00855,A549,Lung adenocarcinoma,Carcinoma,IC50=10.8±1.9 μM,RRWCFRVCYKGFCYRKCR,18,horseshoe crab Limulus polyphemus,Native peptide,Anticancer,ACP##Tumor active peptide,2430.96,2429.18,10.10,ADEHILMNPQST,R,C108H164N36O21S4,7,"Ext. coefficient     8730##Abs 0.1% (=1 g/l)   3.591, assuming all pairs of Cys residues form cystines##Ext. coefficient     8480##Abs 0.1% (=1 g/l)   3.488, assuming all Cys residues are reduced","1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",58.98,16.11,-0.800,30486233++Cytotoxic Potential of the Novel Horseshoe Crab Peptide Polyphemusin III++10.3390/md16120466++2018,0,PM II,Free,Free
DCTPep01095,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Cytotoxicity=12 µM,ALWKNMLKGIGKLAGQAALGAVKTLVGA,28,Dermaseptins B,Native peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide,2780.41,2778.63,10.48,CDEFHPRSY,A,C127H219N35O32S1,4,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.978,"4.4 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-7.19,125.71,0.657,"9614066++Structure, synthesis, and molecular cloning of dermaseptins B, a family of skin peptide antibiotics++10.1074/jbc.273.24.14690++1998",0,DRS B3,Free,Free
DCTPep01377,BXPC-3 ,Pancreatic ductal adenocarcinoma,Carcinoma,IC50=3.2±0.4μM,KQLIRFLKRLDRNGGGKLLLKLLKKLLKLLKKK,33,Synthetic,Synthetic peptide,Anticancer,ACP##Tumor active peptide##Cancer targeted peptides,3915.05,3912.62,11.80,ACEHMPSTVWY,L,C184H338N54O38,12,Should not be visible by UV spectrophotometry.,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",5.4,153.64,-0.342,Not available++Not available++Not available++Not available,0,IL4-lytic(L),Free,Free
DCTPep01605,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FAKGVGKVGKKAL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1302.63,1301.82,10.48,CDEHIMNPQRSTWY,K,C61H107N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-29.95,90.00,0.138,Not available++Not available++Not available++Not available,0,FLAK50 Z6,Free,Amidation
DCTPep01620,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,LD50=1000 µg/ml,FAKKLAKKLKKLAKKLAKLALAL,23,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2537.35,2535.74,10.90,CDEGHIMNPQRSTVWY,K,C123H226N32O24,9,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.58,144.78,0.222,Not available++Not available++Not available++Not available,0,SHIVA 10 AC,Free,Free
DCTPep01622,SW480,Colon adenocarcinoma,Carcinoma,LD50=120 µg/ml,FAKKLAKKLKKLAKKLIGAVLKV,23,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2537.35,2535.74,10.90,CDEHMNPQRSTWY,K,C123H226N32O24,9,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-19.97,144.35,0.278,Not available++Not available++Not available++Not available,0,SHIVA 11[(1-16)ME(2-9]-COOH,Free,Free
DCTPep01624,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=170 µg/ml,FAKKLAKKLKKLAKLALAL,19,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2096.76,2095.43,10.78,CDEGHIMNPQRSTVWY,K,C102H186N26O20,7,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-12.87,149.47,0.384,Not available++Not available++Not available++Not available,0,FLAK06 AM,Free,Amidation
DCTPep01627,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=130 µg/ml,FAKKLAKLAKKALAL,15,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1614.09,1613.08,10.60,CDEGHIMNPQRSTVWY,AK,C78H140N20O16,5,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-1.99,137.33,0.500,Not available++Not available++Not available++Not available,0,FLAK44 AM,Free,Amidation
DCTPep01629,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FAKKLAKLAKKLAKAL,16,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1742.27,1741.17,10.70,CDEGHIMNPQRSTVWY,K,C84H152N22O17,6,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-6.54,128.75,0.225,Not available++Not available++Not available++Not available,0,FLAK26-D2,Free,Amidation
DCTPep01633,PC-3,Prostate carcinoma,Carcinoma,LD50=19 µg/ml,FAKKLAKLAKKLAKLALAL,19,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2039.67,2038.38,10.70,CDEGHIMNPQRSTVWY,AKL,C99H179N25O20,6,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-8.4,154.74,0.684,Not available++Not available++Not available++Not available,0,FLAK 25 AM,Free,Amidation
DCTPep01641,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FAKLAKKLL,9,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1031.35,1030.69,10.30,CDEGHIMNPQRSTVWY,KL,C51H90N12O10,3,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-9.98,152.22,0.678,Not available++Not available++Not available++Not available,0,FLAK83M,Free,Amidation
DCTPep01648,SW480,Colon adenocarcinoma,Carcinoma,LD50=115 µg/ml,FAKLLAKALKKFL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1490.94,1489.97,10.48,CDEGHIMNPQRSTVWY,KL,C75H127N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.83,143.08,0.815,Not available++Not available++Not available++Not available,0,FLAK50 Q6,Free,Amidation
DCTPep01651,BMKC,Skin carcinoma,Carcinoma,LD50=160 µg/ml,FAKLLAKALKLKL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-23.42,173.08,0.892,Not available++Not available++Not available++Not available,0,FLAK 50N,Free,Amidation
DCTPep01653,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=1000 µg/ml,FAKLLAKKLL,10,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1144.51,1143.77,10.30,CDEGHIMNPQRSTVWY,L,C57H101N13O11,3,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.98,176.00,0.990,Not available++Not available++Not available++Not available,0,FLAK80,Free,Amidation
DCTPep01669,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=130 µg/ml,FAKLLAKLAKLKL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1456.92,1455.99,10.48,CDEGHIMNPQRSTVWY,L,C72H129N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-23.42,173.08,0.892,Not available++Not available++Not available++Not available,0,FLAK 50G,Free,Amidation
DCTPep01670,BMKC,Skin carcinoma,Carcinoma,LD50=11 µg/ml,FAKLLALALKLKL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1441.91,1440.98,10.30,CDEGHIMNPQRSTVWY,L,C72H128N16O14,3,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-23.42,203.08,1.485,Not available++Not available++Not available++Not available,0,FLAK50I,Free,Amidation
DCTPep01671,BMKC,Skin carcinoma,Carcinoma,LD50=445 µg/ml,FAKLLFKALKKAL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1490.94,1489.97,10.48,CDEGHIMNPQRSTVWY,KL,C75H127N17O14,4,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-15.39,143.08,0.815,Not available++Not available++Not available++Not available,0,FLAK50 Q2,Free,Amidation
DCTPep01679,PC-3,Prostate carcinoma,Carcinoma,LD50=125 µg/ml,FALAKLAKKAKAKLKKALKAL,21,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2253.93,2252.52,10.85,CDEGHIMNPQRSTVWY,K,C108H197N29O22,8,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-6.65,126.19,0.152,Not available++Not available++Not available++Not available,0,FLAK05 AM,Free,Amidation
DCTPep01680,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=1000 µg/ml,FALALKA,7,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,732.92,732.45,8.75,CDEGHIMNPQRSTVWY,A,C36H60N8O8,1,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-3.56,154.29,1.700,Not available++Not available++Not available++Not available,0,FLAK94,Free,Amidation
DCTPep01681,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,FALALKAKKL,10,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1102.43,1101.73,10.30,CDEGHIMNPQRSTVWY,AKL,C54H95N13O11,3,Should not be visible by UV spectrophotometry.,"1.1 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",-7.98,147.00,0.790,Not available++Not available++Not available++Not available,0,FLAK-120C,Free,Amidation
DCTPep01722,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=135 µg/ml,KLLKLLLKLYKKLLKLL,17,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,2081.83,2080.48,10.40,ACDEFGHIMNPQRSTVW,L,C105H193N23O19,6,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   0.716,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-30.54,229.41,0.782,Not available++Not available++Not available++Not available,0,FLAK100-CO2H,Free,Free
DCTPep01724,SW480,Colon adenocarcinoma,Carcinoma,LD50=240 µg/ml,KWKKLAKKW,9,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1215.55,1214.77,10.60,CDEFGHIMNPQRSTVY,K,C61H98N16O10,5,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   9.049,"1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",-0.54,54.44,-1.744,Not available++Not available++Not available++Not available,0,FLAK120,Free,Amidation
DCTPep01732,NCI-H1299,Lung large cell carcinoma,Carcinoma,LD50=120 µg/ml,LPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG,38,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,4070.97,4068.46,10.73,CDHMQSTY,K,C189H322N54O45,7,Ext. coefficient     5500##Abs 0.1% (=1 g/l)   1.351,"5.5 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",25.44,115.53,0.042,Not available++Not available++Not available++Not available,0,LSB-37,Free,Amidation
DCTPep01742,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,LD50=45 µg/ml,VAKLLAKALKKLL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1408.88,1407.99,10.48,CDEFGHIMNPQRSTWY,L,C68H129N17O14,4,Should not be visible by UV spectrophotometry.,"100 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",-10.36,195.38,1.000,Not available++Not available++Not available++Not available,0,FLAK50D V,Free,Amidation
DCTPep01751,BMKC,Skin carcinoma,Carcinoma,LD50=1000 µg/ml,YAKLLAKLAKKAL,13,FLAK peptides,Synthetic peptide,Anticancer; Antibacterial; Antifungal,ACP##Tumor active peptide,1430.84,1429.94,10.18,CDEFGHIMNPQRSTVW,AKL,C69H123N17O15,4,Ext. coefficient     1490##Abs 0.1% (=1 g/l)   1.041,"2.8 hours (mammalian reticulocytes, in vitro).##10 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",14.38,150.77,0.423,Not available++Not available++Not available++Not available,0,FLAK50T9,Free,Amidation
DCTPep02038,MGC-803,Gastric mucinous adenocarcinoma,Carcinoma,Observed by scanning electronic microscopy,AMVGT,5,Eisenia fetida,Native peptide,Anticancer; Antimicrobial; Antifungal,Cancer therapy related peptides,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not available++A novel antimicrobial vermipeptide family from earthworm Eisenia fetida++10.1016/j.ejsobi.2007.08.048++2007,0,EP3,Acetylation,Free
DCTPep02039,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,19 ± 2.82% Inhibition=160 μM,CHHNLTHAC,9,Synthetic,Synthetic peptide,Anticancer,Cancer targeted peptides##PTPRJ agonist,1035.16,1034.42,7.00,DEFGIKMPQRSVWY,H,C41H62N16O12S2,3,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.121, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",120.24,54.44,-0.356,23627474++Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation++10.1021/cb3007192++2013,0,PTPRJ pep-19,Free,Free
DCTPep02046,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,20 ± 1.4% Inhibition=160 μM,CHHNLTAAC,9,Synthetic (Derived from PTPRJ pep-19),Synthetic peptide,Anticancer,Cancer targeted peptides##PTPRJ agonist,969.1,968.4,6.90,DEFGIKMPQRSVWY,ACH,C38H60N14O12S2,2,"Ext. coefficient      125##Abs 0.1% (=1 g/l)   0.129, assuming all pairs of Cys residues form cystines##Ext. coefficient        0##Abs 0.1% (=1 g/l)   0.000, assuming all Cys residues are reduced","1.2 hours (mammalian reticulocytes, in vitro).##>20 hours (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",120.24,65.56,0.200,23627474++Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation++10.1021/cb3007192++2013,0,PTPRJ pep-19.7,Free,Free
DCTPep02174,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,IC50=35 µM,RIIDLLWRVRRPQKPKFVTVWVR,23,Sus scrofa,Native peptide,Anticancer; Antimicrobial; Antifungal,ACP##Tumor active peptide,2962.63,2960.78,12.18,ACEGHMNSY,R,C140H229N43O28,6,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   3.713,"1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",50.85,118.26,-0.296,"12054589++Design of novel peptide analogs with potent fungicidal activity, based on PMAP-23 antimicrobial peptide isolated from porcine myeloid++10.1016/S0006-291X(02)00222-X++2002##20512598++C-terminal amidation of PMAP-23: translocation to the inner membrane of Gram-negative bacteria++10.1007/s00726-010-0632-1++2011",0,"PMAP-23, Myeloid antibacterial peptide 23",Free,Amidation
DCTPep02256,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,IC50=132.3 µM,RRWKIVVIRWRR,12,Synthetic,Synthetic peptide,Anticancer; Antimicrobial,ACP##Tumor active peptide,1724.14,1723.07,12.60,ACDEFGHLMNPQSTY,R,C80H134N30O13,6,Ext. coefficient    11000##Abs 0.1% (=1 g/l)   6.380,"1 hours (mammalian reticulocytes, in vitro).##2 min (yeast, in vivo).##2 min (Escherichia coli, in vivo).",185.95,113.33,-0.900,23478953++Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides++10.1128/AAC.00175-13++2013,0,PL-D 38,Free,Free
DCTPep02325,BFTC-905,Bladder carcinoma ,Carcinoma,~40% Cell death=40 µg/ml,KRKCPKTPFDNTPGAWFAHLILGC,24,Lactobacillus casei; Lactobacillus paracasei,Native peptide,Anticancer; Antibacterial,ACP##Tumor active peptide##Induce apoptosis,2701.2,2699.38,9.39,EMQSVY,KP,C124H190N34O30S2,4,"Ext. coefficient     5625##Abs 0.1% (=1 g/l)   2.082, assuming all pairs of Cys residues form cystines##Ext. coefficient     5500##Abs 0.1% (=1 g/l)   2.036, assuming all Cys residues are reduced","1.3 hours (mammalian reticulocytes, in vitro).##3 min (yeast, in vivo).##3 min (Escherichia coli, in vivo).",41.77,57.08,-0.333,25557887++Antimicrobial peptide m2163 or m2386 identified from Lactobacillus casei ATCC 334 can trigger apoptosis in the human colorectal cancer cell line SW480++10.1007/s13277-014-3018-2++2015,0,m2163,Free,Free
DCTPep02363,A549,Lung adenocarcinoma,Carcinoma,LC50>100 µM,ILGAILPLVSGLLSNKL,17,Alytes obstetricans,Native peptide,Anticancer; Antibacterial; Antifungal,Cancer therapy related peptides,1721.16,1720.09,8.75,CDEFHMQRTWY,L,C81H145N19O21,1,Should not be visible by UV spectrophotometry.,"20 hours (mammalian reticulocytes, in vitro).##30 min (yeast, in vivo).##>10 hours (Escherichia coli, in vivo).",47.34,206.47,1.553,22392897++Analogues of the frog skin peptide alyteserin-2a with enhanced antimicrobial activities against Gram-negative bacteria++10.1002/psc.2397++2012,0,Alyteserin-2b,Free,Amidation
